Podcasts about Pyxis

Charles Cullen was supposed to keep patients alive. Instead, he became one of America's most prolific serial killers. In Part 1 of this two-part series, Marina's sister Lisa is back by popular demand to tell the story of Cullen's troubled early life, his path into nursing, and the suspicious deaths that followed him from hospital to hospital. By the time Somerset Medical Center started questioning his use of the Pyxis machine, the true scope of the horror is only starting to come into focus.

“Give Me Liberty or Give Me Death!” - Patrick Henry  Honoring Innovation, Freedom, and Small Business on the 4th of July  In this special Independence Day episode of Scaling UP! H2O, host Trace Blackmore brings you a rich blend of patriotism, professional insight, and entrepreneurial spirit. Opening with reflections on July 4th traditions—from fireworks to parades—Trace sets the stage for a compelling conversation with Jack Clark, Owner and Founder of 180 Water. As the water industry faces growing demand and generational turnover, Jack offers a bold solution: a replicable franchise model designed to preserve institutional knowledge and sustainably expand access to clean water. A Rancher Turned Water Well Visionary  Jack shares his origin story, from growing up on a ranch in Montana to launching a water well drilling company that now spans multiple states. What started with a neighbor's influence and a deep respect for self-reliance evolved into a career in well drilling—and eventually, a scalable business framework. Jack walks us through the unique challenges of finding water in fractured rock regions and explains how field wisdom, data monitoring, and humility define success. Franchising in the Water Sector: Solving the Knowledge Drain  As the industry grapples with aging experts nearing retirement, 180 Water is addressing a critical issue: the loss of operational and geological expertise. Jack reveals how his team is onboarding retiring professionals as equity partners to serve as regional hubs, blending mentorship with modern operations. Their approach enables local ownership, data collection, and scalable customer service, while preserving regional nuances in well drilling. Lessons in Leadership, Accountability, and Resilience  Jack emphasizes that real growth stems from reflection, mentorship, and integrity. He discusses how accountability—rooted in ranch life—translates into transparent client relationships, responsible site practices, and support systems that empower franchisees. His goal? To build a network of highly trained, values-aligned professionals who ensure the longevity and safety of our groundwater resources. The Spirit of Liberty: Patrick Henry's Enduring Speech  In a moving tribute to Independence Day, Trace closes the episode with a complete reading of Patrick Henry's “Give Me Liberty or Give Me Death” speech. Listeners are reminded of the courage it takes to challenge the status quo and the unifying power of respectful discourse—values that echo through today's challenges in water, business, and beyond. Final Takeaway  This episode isn't just about wells—it's about vision, responsibility, and the courage to lead. Jack Clark's journey inspires water professionals to think bigger, act with purpose, and consider scalable solutions to systemic industry issues.  Be sure to check our events page for upcoming water conferences and symposiums to continue growing your expertise.  Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps    02:20 - Trace Blackmore shares his warm greetings to Scaling UP! Nation this 4th of July! 07:27 - Upcoming Events for Water Treatment Professionals   10:37 - Water You Know with James McDonald  12:53 - Introduction with Jack Clark of 180 Water 18: 07 - Jack transitioned from expansion by employment to a franchise model   Quotes  Jack Clark: “If you don't get your chores done on the farm, things don't eat. And so it's important to make sure that you can be counted on.” “I was sending my best guys to the worst projects, my worst guys to the best projects—and no one was happy.” “You know how to run your business. You were successful at that. But we want to help you scale it with support and mentorship.” “There's not a perfect science to well drilling. Sometimes you find the water. Sometimes you don't. But that's the responsibility we take on.”  Trace Blackmore: “I really believe that the backbone of our country is small business and entrepreneurship.” “I hope we realize we have way more in common than we do differences—and that we enter conversations with curiosity instead of judgment.”    Connect with Jack Clark  Phone: +406 465 4791   Email: jack.clark@180water.com  Website: 180 Water   LinkedIn: 180 Water: Overview | LinkedIn    Click HERE to Download Episode's Discussion Guide    Guest Resources Mentioned  Freakonomics: A Rogue Economist Explores the Hidden Side of Everything by Steven D. Levitt, Stephen J Dubner    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind    Water You Know with James McDonald  Question: How many ppm of sodium sulfite does it take to react with one ppm of oxygen?   2025 Events for Water Professionals   Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.     

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

01.The Future Sound Of London – Papua New Guinea (Nu:Tone RMX) 02.Jamiroquai – Too Young To Die (Rowpieces RMX) 03.Thundercat – Funny Thing (DJ Marky & Makoto RMX) 04.Subrix – Memories 05.Tim Cant – Griffters 06.Twintone – Ichamel Pt 1 07.Weynorx – Morning Dawn 08.Soulph8 – Desire 09.Michael Jackson – Human Nature (HumaNature Bootleg) 10.Wez Walker – Give Me Something 11.ALB – Falling 4 U 12.DJ Jazzy Jeff & The Fresh Prince – Summertime (Al Pack Bootleg) 13.Dramatic – Park Theme 14.Eddy Don't Sail – The Way It Was 15.Iskia – God's Love 16.Kontrast – Soulflyer 17.Liquefaction – Shadows (Shunna RMX) 18.Mage – Lost Inside 19.Aleyum & Philith – Dynasty 20.Makoto – Watercolour 21.Misland – Slipping Away 22.Pyxis & Camagro – True North 23.Redemptive – Think About It 24.4HZ – About The Flow (Shaki RMX) 25.Technimatic – When You Love Me 26.Screamarts – Sun Dance 27.Loxy VS Spirit – Caution (DJ Garland's Edit)

“You don't have to transition your entire business. You just need to start. Small beginnings are okay.”  Revolutionizing Water Treatment Through Smart Tech  In this episode of Scaling UP! H2O, host Trace Blackmore welcomes Kevin Kuhne, Founder and President of Energy Resource Products, LLC, for a deep-dive conversation on the emerging role of smart technology and artificial intelligence in water treatment.  With decades of experience leading tech-driven innovation, Kevin unpacks how intelligent systems, edge computing, and real-time data processing are reshaping operations in the field—from cooling towers to complex distribution networks.  Whether you're managing plant performance or driving strategic growth, this episode offers a credible look into the future of industrial water management.   From Controllers to Edge-Based Intelligence  Kevin introduces the evolution of traditional controllers into what he calls “computers at the edge.” These intelligent systems collect real-time data, deliver predictive alerts, and can execute secure firmware updates—all without requiring field visits. This shift eliminates the dependency on gateways and streamlines site management through centralized dashboards, saving time and resources.  He illustrates how these systems not only detect pump failures before they occur but also reduce chemical overdosing incidents by offering immediate visibility into feeder issues and sensor discrepancies.   Breaking the Barrier: Selling Smart Tech to Stakeholders  One of the recurring challenges in adopting new technology is overcoming skepticism—especially from IT teams and procurement stakeholders. Kevin outlines strategies for simplifying the sales conversation: focus on specific ROI outcomes like labor savings, chemical usage reduction, and improved equipment uptime. He also breaks down how modern security protocols and machine-to-machine communication are easing concerns around connectivity and data protection.   AI and the Cloud: Turning Data into Action  The discussion advances into how AI-enabled platforms now process disparate data streams in the cloud to support smarter decision-making. Rather than waiting for weekly reports, professionals can now access dynamic dashboards and build customized data visualizations to proactively manage client sites from any location.  Kevin emphasizes that this shift empowers service professionals, not replaces them. By removing manual data bottlenecks, smart tech allows for more impactful engagement and long-term client retention.  Future-Proofing the Industry  Kevin predicts a near future where IO configurations fade, sensors become brand-agnostic, and user interfaces resemble common mobile apps. He encourages water professionals to begin small—pilot smart technology in a single location, gather feedback, and use those wins to accelerate broader adoption.  He closes with a message for early-career professionals: embracing smart technology from the start will enable them to deliver higher value and grow their impact in the industry.   Conclusion  As industries move toward intelligent infrastructure, water professionals must adapt. This episode provides a grounded, expert-led perspective on how to practically and securely implement these technologies. For technical managers, engineers, and company leaders, this is a timely and strategic conversation you won't want to miss.  Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps    01:38 – Trace Blackmore shares a reflection on sharks and ecosystem sustainability, tying into the episode's broader theme of technology and responsible action.   10:06 – Water You Know with James McDonald  11:30 – Upcoming Events for Water Treatment Professionals   14:08 – Interview with Founder, President, and Coach Kevin Kuhne of Energy Resource Products  16:11 - Kevin defines smart tech, contrasting traditional controllers with edge-based computing that delivers real-time data, predictive analysis, and remote access  33:10 — Future technology trends 36:12 — Message for newcomers: Kevin encourages young professionals to embrace tech as a tool for empowerment, not a threat    Quotes  “Your customer is already integrating AI in other parts of their business. If we're not doing it, someone else will.”   “Security is the real roadblock, but if the equipment has a computer-type base of operation, IT is far more comfortable.”  “Smart tech is identifying those areas that we can enhance information, translate it, and then act on it.”    Connect with Kevin Kuhne  Phone: 17632263945  Email: kevin@energyresourceproducts.com   Website: www.energyresourceproducts.com    LinkedIn: www.linkedin.com/in/kevin-kuhne-1812626   Click HERE to Download Episode's Discussion Guide    Guest Resources Mentioned   12 Rules for Life: An Antidote to Chaos: Jordan B. Peterson   The Problem of Pain by C.S. Lewis  A Christmas Carol (Collins Classics) by Charles Dickens    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind  AWT Technical Training (Coming Soon - 2026)   422 Inside the Association of Water Technologies with John Caloritis    Water You Know with James McDonald   Question: What is the breakpoint chlorination ratio of chlorine to ammonia required to reach a true free chlorine residual?    2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.   

Sit and rest. Breathe deep. For this will be the last time you get to do so before the world changes. This is how the story begins. This is how the story ends. Content warnings for this episode include: intensive exploration of death // multiple depictions of substance use // discussion of overdosing // allusions to and discussion of suicide // romance // heartbreak // parent-child conflict // grief & lossThis episode is a particularly heavy one - please take care of yourself and access safe supports as needed. Godkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

In this episode of Scaling UP! H2O, host Trace Blackmore interviews Jake Deak, Marketing & Inside Sales Director at Pyxis Lab, for a deep dive into how innovation is born—not in labs, but in the field. Jake shares the story of Pyxis Lab's rapid evolution from a lean, hands-on team to an industry leader in developing smart, user-informed water treatment technology.   Building Solutions from Real-World Problems  Jake Deak's journey began during the pandemic, stepping into a role shaped by both legacy and urgency. Working closely with his father and the Pyxis team, he reveals how their approach centers around listening intently to water treatment professionals and designing products that directly solve the problems they face.  From the ST500 sensor to the OxiPanel, Jake breaks down how each product starts with a call from the field—an operator struggling with membrane fouling, or a technician frustrated by unreliable chlorine measurements. Pyxis doesn't stop at fixing problems; it uses those challenges as fuel for continuous R&D cycles, bringing hardware, firmware, and app-based solutions to life.   Innovation Through Collaboration and Core Values  The success of Pyxis Lab isn't just about technology—it's about a culture deeply rooted in empathy and real-world experience. Jacob discusses the importance of maintaining strong core values and explains how hiring practices focused on field expertise led to better tools and better service for end users.   From Product Development to Media Innovation  Leveraging his media background, Jacob also reveals the upcoming launch of Pyxis Lab's new podcast, "In The Flow." Created to foster industry education and dialogue, this initiative underscores the company's commitment to advancing the water treatment profession through open communication and shared knowledge.   A Clear Takeaway  If there's one message that defines this episode, it's that the best innovations don't begin in isolation—they begin with a conversation. Whether it's a technician venting a daily frustration or a field team asking “what if?”, Pyxis Lab listens and acts. And as Jake reminds us, the future belongs to those who adapt, engage, and stay relentlessly curious.   Conclusion  Jacob Deak exemplifies the spirit of innovation that is reshaping the water treatment industry. Through passion, practicality, and persistence, his work at Pyxis Lab offers a compelling model for how technology and human experience can work hand in hand to create better solutions for water professionals worldwide.  Continue expanding your professional knowledge by subscribing to "Scaling UP! H2O" and exploring "In The Flow" by Pyxis Lab. Stay informed, stay innovative, and stay connected to the evolution of water treatment excellence. Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps  02:17 – Trace Blackmore reflects on eight years of Scaling UP! H2O, building a global community for industrial water treaters  05:10 – Announcement of New Detective H2O Episodes coming for Industrial Water Week  08:04 – Upcoming Events for Water Treatment Professionals   10:15 – Water You Know with James McDonald  12:50 – Introduction to Jake Deak: Background, Family Influence, and Career Journey  16:16 – Core Values at Pyxis Lab and how they shape product development and customer relationships  17:07 – Inside the creation of the OxiPanel Plus   27:14 – Why Pyxis Lab developed a mobile app   29:37 – In the Flow, Pyxis Lab's new education podcast series    Quotes  "When I started this podcast eight years ago, I had no idea how much it would mean to so many people." - Trace Blackmore “If you can envision a staircase in front of you, the very first step is about ten feet tall. But once you take it, you're on your way.” — Trace Blackmore  "We don't just create content; we create community."  "Starting is always the hardest step."  "Data is king. The more we can help operators harness their data, the better decisions they'll make."  "We're not just adapting to change; we're leading it." “We are the friend to the water treater—the friend to the end user—and that has led to a lot of new acquisitions for us.” — Jacob Deak    Connect with Jake Deak  Phone: +15704197057  Email: jacob.deak@pyxis-lab.com   Website: Inline & Handheld Analytical Tools for Water Treatment | Pyxis Lab®  LinkedIn: https://www.linkedin.com/in/jacobddeak/   Click HERE to Download Episode's Discussion Guide    Guest Resources Mentioned   The Outsider by Stephen King  Dark Half by Stephen King  Under The Dome Stephen King  “In the Flow” Podcast by Pyxis Lab  2022 AWT Innovation Award Recipient  Episode 1 In The Flow : Trace Blackmore  ST-500 Inline PTSA Sensor  FS-100/101 Series Ultrasonic Flow Meters  PRL-100 Personal Radar Level Sensor  uPyxis App: Water Tech for Modern World    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  2024 AWT Innovation Award Recipient    Water You Know with James McDonald  Question: Are conductivity and Total Dissolved Solids the same thing?    2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.   

Discover how Mental Health Cooperative (MHC) in Nashville transformed their behavioral health care delivery with the eClinicalWorks 24-hour care module. In this episode, we welcome Megan Isham, Senior Clinical Systems Manager at MHC, who shares their transformative journey and the impact of this tool on their operations. With the growing recognition of behavioral and mental health, it's crucial to understand that delivering mental healthcare involves a broad spectrum of services. From outpatient therapy and counselling to crisis management, detox, and residential programs, each service comes with unique requirements. This podcast dives into how MHC has leveraged these capabilities to enhance their service delivery and improve health outcomes. Megan details how the Behavioral Health (BH) module has streamlined workflows, integrated care episodes, and customized protocols to meet the specific needs of their diverse patient population. She explains how the system's web-based nature allows their field staff to access vital tools in real time, significantly increasing efficiency and care quality. Key highlights include the seamless integration with Pyxis™ for medication management, customizable Progress Notes, and specialized order sets that cater to both inpatient and outpatient needs. Megan also discusses the innovative approaches to patient safety and the efficient management of complex cases through electronic safety plans and real-time census tracking. This episode is packed with valuable insights into how MHC's adoption of the BH module has been a game changer, delivering comprehensive services that truly made a difference.

We're always so concerned about looking back. But what happens when we look forward? Are you the person you wish to be? Will you forgive yourself if you're not?Content warnings for this episode include: grief // complex relationship dynamics // concealment of identity // love & romance // memory lossGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. In this episode, Katani/Nepthysaket is played by Em Carlson & Inanis Andrade is played by Jannes Wessels. For more of these characters, go listen to our first series, Oblivion, which you can find on your favourite podcast app. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

“Keep it simple because the more complex things get, the less people will do it” - Gary Garcia For years, water treatment professionals have relied on PTSA tracers to estimate system performance, but emerging technologies are offering clearer, more direct answers. In this episode of Scaling UP! H2O, host Trace Blackmore welcome once again returning guest Garret "Gary" S. Garcia of Masters Company, now a business unit of MFG Chemical to explore how fluorescent tagged polymers are revolutionizing the way water treaters monitor system health and chemical performance. With decades of expertise, Gary offers practical insights into this game-changing technology.   Why Tagged Polymers Matter  Trace and Gary discuss the limitations of relying solely on PTSA tracers, a method that only indicates product presence rather than active ingredient performance. Gary explains how fluorescent tagged polymers, by chemically bonding the fluorophore to the polymer backbone, provide a direct and reliable measure of active polymer concentration, helping water treaters make more informed service decisions.   Instrumentation and Integration Challenges  Listeners will gain a practical understanding of how to implement tagged polymer technology. Gary outlines how existing probes and meters compare, what calibration and integration may look like, and whether both PTSA and tagged polymers can be used together. He also explains why tagged polymers are especially useful in systems impacted by iron, cationic biocides, or inconsistent load demands.    Real-World Applications and Benefits  Tagged polymers make it possible to move beyond "set-it-and-forget-it" dosing practices. Gary discusses how accurate polymer monitoring can reduce overfeeding, optimize chemical performance, and improve system health. For both QC in manufacturing and daily service checks, these tools offer better visibility into what's really happening inside the system.    The Simplicity of Switching  Gary highlights the ease of adopting tagged polymers – often a direct drop-in with no reformulation needed. For water treaters, that means minimal disruption and an immediate opportunity to upgrade their programs.   Conclusion  Fluorescent tagged polymers are not just another tool in the toolbox; they represent a critical step forward in water treatment precision and reliability. As Gary notes, understanding and adopting these technologies allows professionals to elevate their programs, save resources, and better serve their customers.  Continue advancing your technical expertise. Explore additional Scaling UP! H2O episodes, stay updated on innovations in water treatment, and connect with leaders like Gary Garcia who are shaping the future of the industry. Visit scalinguph2o.com to access more resources and educational discussions. Stay engaged, keep learning, and continue scaling up your knowledge!   Timestamps  01:55 – Trace reflects on last week's episode of Ben Frieders' talking about fire safety advice.   08:03 – Water You Know with James McDonald  09:33 – Upcoming Events for Water Treatment Professionals  13:01 – Interview with returning guest Gary Garcia of Master's Company   15:39 – Volunteering and Career growth through AWT  18:22 – Differences between PTSA and fluorescent tagged polymers  28:43 – Misconceptions about single-parameter testing with PTSA  34:01 – How to learn more and connect with experts like Gary Garcia   Quotes  “For every ounce of effort you put in, you get 10, 20 ounces back in return.”  Garcia  “We're the good guys. We're helping people save water, energy, helping the environment.”   “When you're measuring for the fluorescent tagged polymer, you're actually measuring for the active ingredient.”   “You gain more information; you gain more expertise. No one person has it all.”   Connect with Garret S. Garcia  Phone: 16302389292  Email: gary@masterscoinc.com  Website: www.masterscoinc.com  Click HERE to Download Episode's Discussion Guide    Guest Resources Mentioned   314 2023 Water Industry Updates  206 The One That's All About Customer Solutions In A Drum    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind    Water You Know with James McDonald Question: What field test is used to measure how likely a water source is to foul reverse osmosis membranes due to suspended solids?   2025 Events for Water Professionals   Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE. 

Pyxis Tankers - Ready for Strategic Expansion Friday, May 23, 2025 Featuring: Mr. Valentios "Eddie" Valentis, Chairman and CEO - Pyxis Tankers, Inc. (NASDAQ: PXS) Mr. Nicolas Bornozis, President - Capital Link About PXS: The Company currently owns a modern fleet of six mid-sized eco-vessels, which are engaged in the seaborne transportation of a broad range of refined petroleum products and dry-bulk commodities and consists of three MR product tankers, one Kamsarmax bulk carrier and controlling interests in two dry-bulk joint ventures of a sister-ship Kamsarmax and an Ultramax. The Company is positioned to opportunistically expand and maximize its fleet of eco-efficient vessels due to significant capital resources, competitive cost structure, strong customer relationships and an experienced management team whose interests are aligned with those of its shareholders. For more information visit here: www.pyxistankers.com. About Trending News: This Webinar Series features interviews and discussions with senior management elaborating on recent company news and announcements, and market trends. For more episodes please visit here: https://capitallinkshipping.com/trending-news/

When the time comes, they'll know you did what you needed to. You did it for the right reasons, and you let the tears come anyway. One for the lonely. One for the heartbroken. One for that which will never be. And one for those who are left behind. Content warnings for this episode include: grief & loss // child abandonment // romance // heartbreak // substance use // lies & concealment of identity // being watched // allusions to sex // rejection // religious undertones // death & a funeral // the woods // complex family dynamics // Godkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character & Location Leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

Hoy en el Daily: Panasonic lanza las Lumix S1 II y S1 II E con grabación open gate en 5.1K y 6K; ARRI actualiza su ecosistema ECS con mejoras en dioptrías, nudges y compatibilidad de lentes; C7adapters presenta una montura PL para cámaras Blackmagic PYXIS y cerramos con una oferta irresistible en el Sigma 45mm f/2.8 para Sony E.

Corrosion control is fundamental to the success of any water treatment program, but how often do we question the limitations of the tools we rely on? In this episode of Scaling UP! H2O, host Trace Blackmore welcomes back returning guest Mike Standish, Vice President of Water Additives at MFG Chemical, to explore the evolving role of maleic acid-based corrosion inhibitors in industrial water treatment. Drawing on decades of expertise, Mike shares practical insights into when — and when not — to use these innovative solutions to meet today's complex challenges. Understanding the Corrosion Control Toolbox  Mike Standish opens the conversation by reframing corrosion control strategies through the lens of a toolbox analogy. With limited primary approaches — from phosphate-based to organic and metal-based chemistries — the success of corrosion management depends on matching the right tool to the right application. Mike stresses the importance of avoiding overcomplication and focusing on the fundamental chemical pathways for mild steel protection. Organic vs. Inorganic Approaches  The discussion turns to the critical differences between organic and inorganic inhibitors. While inorganic phosphates remain cost-effective mainstays, organic phosphonates, including maleic acid-derived materials, offer advantages in high pH, high hardness, and oxidizing environments. Mike emphasizes that “organic” in water treatment bears no relation to natural or sustainable products, a frequent misconception among newcomers to the industry. Why Maleic Acid-Based Inhibitors Matter  Maleic acid phosphonates distinguish themselves with exceptional oxidant stability, a feature increasingly necessary as continuous halogenation becomes standard practice. Mike explains the chemistry behind maleic acid derivatives and how the ability to tailor molecular structures creates flexibility for specific field conditions — such as scaling tendencies, pH control, and calcium carbonate formation risks. Best Practices for Application and Measurement  Field success with maleic acid-based inhibitors hinges on proper dosage and testing. Mike shares lessons from real-world trials, emphasizing that underfeeding is a common mistake that compromises corrosion rates. Accurate differentiation between orthophosphate and phosphonate concentrations is vital for precise monitoring, and bench testing must closely simulate real-world surface-to-volume ratios to yield reliable predictions. The Future of Corrosion Control  In a forward-looking discussion, Mike predicts that industry consolidation will trigger a second wave of entrepreneurial water treatment companies. His vision underscores the ongoing need for technical excellence, adaptability, and innovation in corrosion management practices as the industry evolves.  This episode challenges water treatment professionals to rethink their corrosion strategies with a sharper, more informed approach. Maleic acid-based inhibitors are not a universal solution, but when applied thoughtfully, they offer powerful advantages for specific operational demands.   Explore more episodes, challenge your assumptions, and lead the way in advancing our industry's standards of technical excellence. Don't forget to subscribe to Scaling UP! H2O for more expert insights in water treatment.  Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps   02:50 – Trace Blackmore shares a recap from previous episode. He also shares about the AWT Innovation Award   06:40 - Water You Know with James McDonald  08:00 - Upcoming Events for Water Treatment Professionals   12:38 - Welcoming back guest Mike Standish, Vice President of Water Additives – MFG Chemical   15:10 – The Value of True Industry Knowledge vs. Surface Information  23:10 – Starting the Technical Discussion: The Corrosion Control Toolbox Analogy  26:07 – Explanation of anodic vs. Cathodic protection mechanisms  37:35 – Situational Applications: When to use maleic acid-based inhibitors  40:11 – Lessons learned from field trials on dosage and corrosion control  41:28 – Importance of Accurate modeling and Surface-to-volume ratios    Quotes  “You going to get more than you can give” – Mike Standish  “Picking the right tool for the right job” – Mike Standish  "Stepping away from work for a mission trip doesn't just help others—it helps you gain a new perspective." – Mike Standish  “You can't just throw a new additive into a system and hope for the best. You need data, understanding of limits, and clear expectations.”  “There's going to be a second generation of AWT companies as industry consolidation continues.”    Connect with Mike Standish  Phone: (615) 207- 3018  Email: mike.standish@radicalpolymers.com  Website: https://www.radicalpolymers.com/  LinkedIn: https://www.linkedin.com/in/mike-standish-7890627/  Click HERE to Download Episode's Discussion Guide    Guest Resources Mentioned   Mild Steel Corrosion Control using a Maleic-Based Inhibitor  Purposely Built – Introduction of a New Copolymer for Multifunctional Applications Technical Paper     Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind   Legionella Awareness Resources   417 How To Live a Life of Significance: Insights from Aaron Walker  014 The One with Mike Standish   223 Pinks and Blues: Phosphonate Replacements   350 Polymer Perspectives: Understanding Copolymer Innovations in Water Treatment 176 The One About Tagged Polymer Technologies   Water You Know with James   Question: What do you call the large-diameter tube in firetube boilers where the combustion of fuel takes place?    2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.   

Blackmagic didn't disappoint at NAB this year, and we're pretty excited about the new Pyxis 12K. As usual for this podcast, we go deep into the technical capabilities of this new camera, especially with regards to the 12K sensor. Also, OM System is getting into the culinary business? If you enjoy the show and want to contribute to our hosting costs, we'd welcome your support on Patreon. You can check it out here: https://www.patreon.com/cameragearpodcast Want to send us a question or comment, or just learn more about the show? Check out our website at https://cameragearpodcast.com, or email us directly at cameragearpodcast@gmail.com. Notes: OM System Outdoor Monster Curry Review [PetaPixel] Blackmagic Pyxis 12K Tech Specs [Blackmagic] Blackmagic Pyxis Pro Handle [B&H] Blackmagic Pyxis Pro Grip [B&H] Blackmagic's RGBW Sensor Technology Explained [CineD] Pyxis 12K Video Interview [CineD]

“Always test your tools before field use. Side-by-side comparisons ensure repeatability and accuracy.” In this episode of Scaling UP! H2O, host Trace Blackmore delivers an in-depth update on the SteriPen, a widely used tool for water treatment professionals. After overwhelming demand from listeners, we revisit the SteriPen, its capabilities, and its impact on testing organic phosphates and azoles. If you're looking for efficiency, precision, and portability in water testing, this episode is packed with actionable insights.  The Evolution of the SteriPen Learn how the SteriPen became a game-changer in the industrial water treatment industry. Originally designed for hikers, it's now widely adopted for phosphate digestion and azole testing.  SteriPen Classic 3 vs. SteriPen Ultra: Which One Is Right for You? Trace compares the Classic 3 and Ultra models, discussing their battery life, efficiency, usability, and cost-effectiveness. Get clarity on which device suits your testing needs best.   Testing Efficiency: Reducing Time While Maintaining Accuracy Find out how the SteriPen reduces testing time by half while maintaining accuracy, making it a must-have tool for water professionals.  Best Practices for SteriPen Use From choosing the right vials and batteries to ensuring consistent testing results, this segment walks you through practical applications and expert recommendations.  The Future of Water Testing How innovations like the SteriPen and other portable UV tools are reshaping the way industrial water treatment professionals conduct daily testing.  With water testing advancements, efficiency is key. Whether you're new to SteriPen or looking to upgrade, this episode provides valuable insights to optimize your water testing process.  Water professionals deserve better tools. Upgrade your phosphate and azole testing with the right SteriPen for maximum efficiency and accuracy.  Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps 02:28 – Trace Blackmore shares a recap of Episode 414 06:47 – Upcoming Events for Water Treatment Professionals   16:15 – Water You Know with James McDonald  20:45 – Deep dive into SteriPen device: it's history and application 33:29 – Comparison between SteriPen Classic 3 and SteriPen Ultra  36:00 – Testing Procedures for organic and phosphate and azole tests  38:02 – Charging and battery life for both SteriPen models    Connect with Scaling UP! H2O Submit a show idea: Submit a Show Idea LinkedIn: in/traceblackmore/  YouTube: @ScalingUpH2O  Click HERE to download Episode's Discussion Guide      Scaling UP! H2O Resources Mentioned  Ep 046 The One About Phosphate Testing Ep 414 Pinks and Blues: Trace's Phosphate Redux Ep 415 Green Building Updates: What You Need to Know AA Battery Cases Augmenting your testing procedures for Phosphonate and Azole testing AWT (Association of Water Technologies)   Energizer Ultimate Lithium AA Batteries Eowpower 30pcs 50ml Plastic Vial Storage Container  Hach UV Lamp Kit, 115V  Hach Benzotriazole/Tolyltriazole  Hach Orthophospate PhosVer 3  Hach Phosphonate Lithium re-chargeable batteries  Re-chargeable Lithium Batteries with charger  Scaling UP! H2O Academy video courses  Steri Pen Classic 3  SteriPen Ultra  SteriPen Ultra – Katadyn Fact Sheet Submit a Show Idea  The unboxing of everything you need to use the SteriPen in your Phosphonate and Azole testing  Taylor Technologies Test Procedures:  Phosphonate  Taylor Technologies Test Procedures: Azole  World Vision Global 6k for Water    Water You Know with James McDonald Question: Does silica solubility typically decrease or increase with rising temperature?    2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE. 

What is broken can be mended. What is written can be edited. What is lost can be found again. Where did you go, when you let go of my hand? How have you changed now that you've come back?Content warnings for this episode include: fear // allusions to mass death // knives as weapons // murder // allusions to systems of oppression & class struggle // religious overtones Godkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character & Location Leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

So many new gear updates have dropped recently due to NAB Show 2025—it's almost overwhelming to keep track! But don't worry—sit back, relax, and check out this week's episode of FocusCheck for all the highlights and key updates. From cameras and lenses to lighting and software, we've got everything covered in one easy-to-digest episode. Enjoy! Sponsor: This episode is sponsored by FUJIFILM. Check it out at (34:36) Chapters & Articles Mentioned in This Episode: (00:00) -  Intro (02:07) - Blackmagic Design NAB 2025 Update – Join the Live Stream https://www.cined.com/blackmagic-design-nab-2025-update-join-the-live-stream/ (03:29) - Blackmagic PYXIS 12K Camera Explained in Video Interview https://www.cined.com/blackmagic-pyxis-12k-camera-explained-in-video-interview/ (07:16) - Blackmagic PYXIS 12K Camera Price Increased by 32% to $6,595 in the USA Due to Tariffs https://www.cined.com/blackmagic-pyxis-12k-camera-price-increased-by-32-to-6595-in-the-usa-due-to-tariffs/  (10:57) - Immersive Video for Apple Vision Pro with Blackmagic Design URSA Cine Immersive & DaVinci Resolve 20 – Interview https://www.cined.com/immersive-video-for-apple-vision-pro-with-blackmagic-design-ursa-cine-immersive-davinci-resolve-20-interview/ (15:30) - Blackmagic Design PYXIS Top and Side Handles Explained https://www.cined.com/blackmagic-design-pyxis-top-and-side-handles-explained/ (19:27) - DaVinci Resolve 20 Released in Public Beta – with AI-Powered Features https://www.cined.com/davinci-resolve-20-released-in-public-beta-with-ai-powered-features/ (23:49) - FUJIFILM GFX ETERNA Camera Development Update – Internal ND, Hot Swap, Audio, and More https://www.cined.com/fujifilm-gfx-eterna-camera-development-update-internal-nd-hot-swap-audio-and-more/ (35:40) - Tilta Nucleus-M II Introduced – Features a New 4-Channel FIZ Unit, Flexible Motors, and More https://www.cined.com/tilta-nucleus-m-ii-introduced-new-fiz-unit-flexible-motors-and-more/ (40:04) - NiSi AUREUS PRIME T1.4 Cinema Lens Series Introduced – Fast & Full-Frame https://www.cined.com/nisi-aureus-prime-t1-4-cinema-lens-series-introduced-fast-amp-full-frame/ (44:31) - BLAZAR Mantis 1.33x Anamorphic Full-frame Lightweight Lens Series Announced https://www.cined.com/blazar-mantis-1-33x-anamorphic-full-frame-lightweight-lens-series-announced/ (46:57) - DZOFILM X-tract Macro Zoom Probe Lens Introduced – 3 versions, 18-28mm, T8, and Full-Frame https://www.cined.com/dzofilm-x-tract-macro-zoom-probe-lens-introduced-3-versions-18-28mm-t8-and-full-frame/ (49:25) - Laowa Probe Zoom Lenses Introduced – 15-35mm T12 / 15-24mm T8 with Interchangeable Barrel Options https://www.cined.com/laowa-probe-zoom-lenses-introduced-15-35mm-t12-15-24mm-t8-with-interchangeable-barrel-options/ (51:36) - Hollyland LARK MAX 2 – 32-bit Float and Wireless Monitoring https://www.cined.com/hollylands-lark-max-mk-ii/ (55:12) - Saramonic K9 Audio System Debuts with Ultra-Wide UHF Transmission https://www.cined.com/saramonic-k9-audio-system-debuts-with-ultra-wide-uhf-transmission/ (57:56) - Sennheiser Profile Wireless Introduced – All-In-One, Clip-On Microphone System https://www.cined.com/sennheiser-profile-wireless-introduced-all-in-one-clip-on-microphone-system/ (01:00:09) - NANLITE PavoTube II 6XR RGBWW Tubes with CRMX and 8 Pixels Explained https://www.cined.com/nanlite-pavotube-ii-6xr-rgbww-tubes-with-crmx-and-8-pixels-explained/ (01:01:35) - GVM Reign FH400 Introduced – Flat, Lightweight COB Light https://www.cined.com/gvm-reign-fh400-introduced-flat-lightweight-cob-light/ (01:03:17) - Aputure STORM XT52 – First Look at the Brightest LED Fixture Yet https://www.cined.com/aputure-storm-xt52-first-look-at-the-brightest-led-fixture-yet/ (01:05:45) - amaran Pano 120c Presented – a Lightweight, Full Color, LED Light Panel with Multiple Powering Options https://www.cined.com/amaran-pano-120c-presented-a-lightweight-full-color-led-light-panel-with-multiple-powering-options/ (01:08:35) - ASUS ProArt Monitors, a MicroLED Display, and a Display Calibrator Explained https://www.cined.com/asus-proart-monitors-a-microled-display-and-a-display-calibrator-explained/ (01:13:06) - ATOMOSphere, A-Eye PTZ cameras, a TX-RX System, and StudioSonic Headphones Introduced https://www.cined.com/atomos-atomosphere-a-eye-ptz-cameras-a-tx-rx-system-and-studiosonic-headphones-introduced/ (01:18:51) - Strada Agents Introduced – Be Your Own Cloud for Remote Collaboration https://www.cined.com/strada-agents-introduced-be-your-own-cloud-for-remote-collaboration/ We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com

DJ Глюк - Жидкий Драм @ DJ Глюк 1. Peter Lix - Starwalk 2. Onism - Don't Hold Back 3. Duoscience - Facts 4. Jay Dubz - Garden Of Ecstasy 5. Bad 4 Life - Feel So Good 6. Bad 4 Life - Kiss Goodbye 7. Technimatic - From Within 8. Lsb, Etherwood - Evermade 9. Pyxis & Embers of Light - Growing 10. GLXY, Sâlo - Love Lost 11. Substainless - It Never Worked 12. Intelligent Manners, Command Strange - In My Mind 13. Shenji - Golden Glow 14. Pyxis & Heymac - High Enough 15. Pyxis & Blean - Time Travellers

durée : 00:44:34 - En pistes, contemporains ! du dimanche 06 avril 2025 - par : Emilie Munera - Dans votre émission de disques contemporains, retrouvez cette semaine de la nouveauté avec Philippe Quint, l'ensemble Pyxis et le Quatuor Girard. Découvrez aussi du plus ancien grâce à Edward Gardner. - réalisé par : Céline Parfenoff

durée : 00:44:34 - En pistes, contemporains ! du dimanche 06 avril 2025 - par : Emilie Munera - Dans votre émission de disques contemporains, retrouvez cette semaine de la nouveauté avec Philippe Quint, l'ensemble Pyxis et le Quatuor Girard. Découvrez aussi du plus ancien grâce à Edward Gardner. - réalisé par : Céline Parfenoff

durée : 00:44:34 - En pistes, contemporains ! du dimanche 06 avril 2025 - par : Emilie Munera - Dans votre émission de disques contemporains, retrouvez cette semaine de la nouveauté avec Philippe Quint, l'ensemble Pyxis et le Quatuor Girard. Découvrez aussi du plus ancien grâce à Edward Gardner. - réalisé par : Céline Parfenoff

Blackmagic leaks a 12K PYXIS camera just before NAB as the industry prepares for a major trade show. In this episode, hosts Addy Ghani and Joey Daoud dive into pre-NAB announcements, examining Strada's peer-to-peer media sharing tool, Adobe's new AI features, and how Gaussian splats are quietly becoming the next significant technology evolution. Plus, they unpack OpenAI's strategic move into open weights and what it means for enterprise AI adoption.

One link for those you've lost. One link for those you've found. And a link for yourself, to remember what ties you to those around you. We are nothing if not our bonds to each other.Content warnings for this episode include: betrayal // grief & loss // war // romance // blood // body horror // knives as weapons // harm to animals // threats of violence // assisted suicideGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. The voice of Issilus, The Broken Sister, is Aabria Iyengar. The voice of Tharakus, Abyss in Chains, is Si Rutherford. This season's dramaturge is Tim Carlson. This episode was edited, scored, and produced by Si Rutherford. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

"Strategic planning is creating certainty in an uncertain world." – Tim Fulton Strategic planning is essential for success in any business, yet many companies either overlook or struggle with the process. In this episode, Trace Blackmore welcomes back Tim Fulton, President of Small Business Matters, to explore the fundamentals of strategic planning and how businesses can chart their course for success.   Tim shares insights on why strategic planning matters, how to involve the right people, and how to create a plan that actually works. Whether you're a business owner, manager, or part of a team, this episode provides valuable takeaways to help you navigate uncertainty, set clear objectives, and execute effectively. Why Strategic Planning is Critical Strategic planning helps businesses stay focused in an unpredictable world. By analyzing past performance, assessing the present, and setting future goals, companies can adapt to changing markets, industry trends, and emerging technologies like AI. Who Should Be Involved in Strategic Planning? Successful planning requires input from leaders and key employees at different levels. Involving the right people fosters collaboration, avoids blind spots, and ensures that the plan is practical and actionable, rather than created in isolation. The SWOT Analysis: A Tool for Understanding Your Business A SWOT analysis (Strengths, Weaknesses, Opportunities, and Threats) helps businesses understand their position. Identifying strengths and weaknesses within the company, along with external opportunities and threats, provides a clearer strategy for growth and risk management. Executing the Plan & Measuring Success A strategic plan is only effective if it's executed properly. Setting SMART goals (Specific, Measurable, Achievable, Relevant, Time-bound) ensures clarity, while quarterly reviews and color-coded tracking (Green, Yellow, Red) help teams monitor progress. Methods like the 12-Week Year and OKRs (Objectives & Key Results) keep businesses on track and accountable. Why Having a Third-Party Facilitator Can Make a Difference An outside facilitator brings an objective perspective, helping businesses stay focused and engaged during planning. Leaders who try to both facilitate and participate often struggle to balance these roles. Involving an expert improves discussions and strengthens team buy-in. Common Mistakes in Strategic Planning & How to Avoid Them Many businesses fail in strategic planning due to poor communication, lack of follow-through, and ignoring potential risks. A strong plan must be actively maintained throughout the year to ensure long-term success. Tim Fulton joined Trace Blackmore to deliver essential insights into strategic planning, emphasizing clarity, involvement, accountability, and the power of facilitation. This episode challenges listeners to create meaningful strategies, fostering organizational resilience and success in any environment. Stay engaged, keep learning, and continue scaling up your knowledge!   Timestamps    3:00 – Trace Blackmore encourages listeners to help spread the word about Scaling UP! H2O Podcast by sharing it with their colleagues and network 07:00 – Upcoming Events for Water Treatment Professionals 09:12 – Water You Know with James McDonald 11:00 – Interview starts: Welcoming back Tim Fulton 13:12 – What is Strategic Planning? 15:44 – Who should be involved in Strategic Planning? 23:22 – Why should companies strategically plan 34:58 – Best time for strategic planning 40:00 – Objective and Key Results (OKRs) explained   Quotes  "No weigh-in equals no buy-in.” - Patrick Lencioni, quoted by Trace “Fear is the biggest obstacle preventing businesses from strategic planning.” - Tim Fulton “Not having a plan is a plan for failure.” - Trace Blackmore “Doing strategic planning without a facilitator is like being quarterback and referee at the same time.” - Tim Fulton Connect with Tim Fulton Phone: (678) 427- 9436 Email: timfulton@hotmail.com Website: smallbusinessmattersonline.com LinkedIn: https://www.linkedin.com/in/timcfulton/  Click HERE to Download Episode's Discussion Guide     Guest Resources Mentioned The Meeting by Tim Fulton Measure What Matters by John Doerr Traction by Gino Wickman    Scaling UP! H2O Resources Mentioned AWT (Association of Water Technologies) Scaling UP! H2O Academy video courses Submit a Show Idea The Rising Tide Mastermind 022 The One with Tim Fulton   280 The One About Retaining Top Talent   289 The One About A SWOT Analysis with A Twist   368 Adapting to the New Workforce: Attracting Top Talent 164 The One With Chris McChesney What the Heck Is EOS? A Complete Guide for Employees in Companies Running on EOS by Gino Wickman   The 12 Week Year   The Five Dysfunctions of a Team by Patrick Lencioni Water You Know with James McDonald  Question: What do you call the attraction of water molecules to each other that gives water its unique properties, such as a high surface tension, high boiling point, and ability to dissolve many substances?   2025 Events for Water Professionals Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.  

If you have a compass – physical or virtual – let it point you to the southeast as night falls for the constellation Pyxis – the celestial compass. It’s a short line of faint stars, aiming toward the remnants of the Argo – the ship that carried Jason and the Argonauts. In fact, Pyxis represents the Argo’s compass. You need a pretty dark sky to see even its brightest star. But that’s only because the star is about 900 light-years away. If you moved it to the distance of Sirius, the brightest star in the night sky, Alpha Pyxidis would outshine everything except the Sun and Moon. In astronomical parlance, Alpha Pyxis is “class B.” Astronomers classify stars by their surface temperature and color – hot stars are blue, while cool stars look orange or red. The hottest stars are class O, followed by class B. Alpha Pyx is tens of thousands of degrees hotter than the Sun, so it shines blue-white. The star is so hot because it’s more than 10 times as massive as the Sun. At that great mass, gravity squeezes the star tightly, making its interior intensely hot. As a result of those high temperatures, Alpha Pyxidis is “burning” through its hydrogen fuel in a hurry. So even though the star is less than one percent the age of the Sun, it’s already nearing the end of its life. Within a few million years, the star may go out with a bang: a titanic explosion known as a supernova. We’ll have more about Pyxis tomorrow. Script by Damond Benningfield

Your chains are rattling. The walls are crumbling. The Titans are coming, High Priestess... are you ready to do your duty to restore balance?  Content warnings for this episode include: betrayal // grief & loss // lies & concealment // body horror // corruption & possession // graphic violence // premeditated murder // blood // knives as weapons // harm to animals // self harm & allusions to suicide // religious overtones // war // fire // unsafe water // sexual undertones // Godkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. The voice of Issilus, The Broken Sister, is Aabria Iyengar. The voice of Tharakus, Abyss in Chains, is Si Rutherford. This season's dramaturge is Tim Carlson. This episode was edited, scored, and produced by Si Rutherford. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

El sector de las tecnologías de la información necesita personal: se suele hablar de que en esta actividad existe desempleo negativo. Pero las oportunidades no son solo para los jóvenes que están saliendo del liceo y que se pueden enfocar a una carrera vinculada con este rubro. ¿Qué pasa con los mayores de 45 años, los que se quedaron sin trabajo a una edad en la que conseguir empleo de nuevo es más desafiante, o los que quieren simplemente cambiar de rumbo? Después de todo, ¿quién dice que uno tiene que atarse de por vida a un único sendero laboral? Pero, claro, la formación en un área como las TIC no es sencilla para alguien de mediana edad. Y quizás muchas empresas no se animan a tomar personas de ese segmento etario si ellas no tienen ya una trayectoria hecha. Por todo esto, en 2024 se lanzó Talento Tech +45, un programa financiado por Inefop e impulsado por las empresas Talento Senior Uruguay, Pyxis y Haltynea Consulting, que ya formó a 40 personas para reconvertirse en trabajadores TIC y que ahora está buscando sumar firmas“madrinas” para que se complete la inserción laboral. ¿Qué valor le dan al trabajo senior, tanto desde el punto de vista social como empresarial? ¿Por qué los mayores de 45 pueden aportarle valor a las empresas TI? ¿Y cómo lo ven los propios trabajadores “reconvertidos? Lo discutimos En Perspectiva en una nueva edición de La Mesa TIC junto a Ricardo Halty, director general de Haltynea Consulting; Carlos García, analista funcional en Pyxis y entró como parte del programa +50 de la empresa; Ivelise Reinaldo, cofundadora de Talento Senior Uruguay; y Alejandra Zepedeo, referente del programa Talento Tech +45 en Pyxis.

"If you're excellent at what you do, you've got to be paid like you're excellent." – Casey Brown  Ever wondered if you're truly getting paid what you're worth? In this unmissable episode of Scaling UP! H2O, we bring back Casey Brown, speaker, founder of Boost Pricing and author of the newly released Fearless Pricing. Known for her electrifying talks and actionable insights, Casey dives deep into how businesses can build confidence, charge their true value, and break free from the fear of pricing discussions.  From her journey as an engineer to becoming a pricing powerhouse, Casey's passion for helping businesses thrive shines through. Whether you're in sales, management, or leadership, this episode will leave you inspired and ready to tackle your next negotiation.   Highlights include:  The Psychology of Pricing: Why fear dominates most pricing conversations—and how to overcome it. Pricing Integrity: Learn how setting and sticking to fair, defensible prices can boost trust and long-term success. Handling Objections with Confidence: Proven strategies to turn pricing objections into opportunities. The "Hot Sauce" Analogy: Discover how to identify overlooked products or services that can deliver high profits with minimal pricing sensitivity. Unexercised Pricing Power: How to unlock hidden revenue by testing and refining your pricing strategy. Role-Playing for Success: How procedural memory and consistent practice can transform your sales team's confidence and results.  Bottom Line  This episode is your ultimate guide to fearless pricing, equipping you with the tools and mindset to boost profitability and set yourself apart from the competition. Don't miss the chance to learn from Casey's expertise and take your business to the next level!  Click play, take notes, and start commanding the value your business deserves. Don't let fear control your profits—listen now to gain the confidence and strategies you need to succeed. Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps    1:44 - Trace asks intriguing questions about the price of everyday items like gas and hot sauce to set the stage for a deeper discussion on pricing   02:23 - Events for Water Professionals   04:20 - Water You Know with James McDonald   05:35 - Interview with Casey Brown, speaker, founder of Boost Pricing, and the author of the newly released book ‘Fearless Pricing'   13:05 - How small discounts can devastate your bottom line  32:23 - Why debriefing every deal is critical for refining your pricing strategy  33:41 - The “Hot Sauce Analogy”  45:00 – Final Thoughts and Takeaways    Quotes  “We can't know, unless we try. The world is your Petri dish. “- Casey Brown  “The how is training and coaching and concepts; the why is rotted in the mission to help people who are excellent be paid like they're excellent.” - Casey Brown  “We can't fix pricing or profitability through calculation. We must address the biggest obstacle to success, which is FEAR.” - Casey Brown  “Pricing is generally the area of greatest fear and greatest discomfort.” - Casey Brown  “In absence of financial pricing integrity, unearned discounts hurt trust.” - Casey Brown  “The way to get comfortable doing something uncomfortable is to practice it.” - Casey Brown  "Every business has hot sauce and gasoline—products where pricing sensitivity varies drastically. Identify yours." – Casey Brown    Connect with Casey Brown  Phone: 614-679-7999  Email: casey@boostpricing.com   Website: www.Caseybrown.com    LinkedIn: https://www.linkedin.com/in/caseybrownboost/   Subscribe to Casey Brown's Newsletter: https://www.boostpricing.com/signup    Click HERE to Download Episode's Discussion Guide   Guest Resources Mentioned   Good to Great: Why Some Companies Make the Leap...And Others Don't by Jim Collins  They Ask You Answer by Marcus Sheridan  Outlive by Peter Attia  Essentialism by Greg McKeown  The Psychology of Money by Morgan Housel  Fearless Pricing by Casey Brown    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind  363 Pricing Boost: Get Paid Well For Your Excellence with Casey Brown  The 7 Habits of Highly Effective People by Stephen R. Covey    Water You Know with James McDonald  Question: What is the conversion between parts-per-million and milligrams per Liter?   2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.

You don't want to look at it. You don't want to see. But you need to. The Weave has a story for you, and you need to look at it to know. But be careful... while you are watching, who is watching you?Content warnings for this episode include: grief & loss // betrayal // abandonment & rejection // death // corruption & possession // body horror // sleep paralysis // being watched // allusions to child endangerment // Godkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. The voice of Issilus, The Broken Sister, is Aabria Iyengar. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

What's inside you will sustain. What's inside you is a gift. What's inside you is a hope beyond hope. How do you slake your hunger? What would you give to feel whole again?Content warnings for this episode include: food & feeding // grief & loss // betrayal // threats // body horror // family conflict // discussion of attempted murderGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. The voice of Ungal, The Undying is Matthew Mercer. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

Time. You thought you had more time. But between the Scion and the creeping form in the mirror, it has all come too fast. But goodness, aren't you hungry? Are you fed? Eat. Content warnings for this episode include: police brutality // premeditated violence // deceit // power dynamics // forced confinement // corruption // nepotism // hunger & forced feeding & food // being watched // body horror // murder Godkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. The voice of Avaris Kerschel, The Scion of Perdition, is Brennan Lee Mulligan. The voice of Ungal, The Undying, is Matthew Mercer. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

Welcome to a monumental celebration in the world of Drum and Bass with The Stress Factor Podcast episode 320, marking a remarkable 15-year journey since its inception on January 1, 2010. This special episode is a thrilling 60 track studio mix by the renowned DJ B-12, designed to take listeners on an exhilarating auditory adventure. Spanning an impressive hour and 43 minutes, the mix showcases the finest in current upfront, liquid, and electro Drum and Bass, featuring euphoric vocals and stunning melodies that will resonate with both long time fans and newcomers alike. The energy is palpable, and the carefully curated selection of tracks promises to elevate your spirits and keep you moving, making it a perfect soundtrack for any occasion. As a heartfelt thank you to the loyal listeners who have supported The Stress Factor Podcast over the years, this episode is a testament to the community that has grown around it. Special acknowledgments go out to DJ Scottie B and Ste-J, who have been integral to the show since its early days, as well as DJ Tribo and R1 for their invaluable contributions. The episode features minimal talking, allowing the music to take center stage, but it does include a special voice message from the podcast's number one VIP listener, Axel The X Engler, adding a personal touch to this celebratory mix. With plans for a highly anticipated best of mix in February, the excitement continues as The Stress Factor Podcast looks forward to another 15 years of delivering the best in Drum and Bass. Big ups to all who have been part of this incredible journey! This episode contains tracks and remixes from the following artists and on the following labels Makoto, Lauren Archer, Liquicity Records, Nkz, Lizplay Records, Nicky Romero, Vikkstar, Alpharock, Oaks, Rameses B, Protocol Recordings, Genemo, YUNA, Saralia, Munix Records, Freaks Geeks, Flowidus, Gia Santho, Elevate Records, AL SO, Plasmator, Manifest, Andromedik, Lauren L'aimant, Akos Gyorfy, Kelle, Celsius Recordings, Friction, Circadian, Fallen State, Mathematica Records, Kleu, LoveThatBass, Receptor, Paperclip, Paperfunk Recordings, Voicians, Gentlemens Club, Lee Mvtthews, DnB Allstars, Marble Elephant, Monika, Spearhead Records, Cyazon, Gracie Van Brunt, Bassrush Records, K2T, DA TU, Offworld Recordings, Technimatic, Zara Kershaw, Keeno, Polaris, Keeno Music, Koven, AEON MODE, Monstercat, Modest Intentions, Formulus, Park Shadow, Straight Up Breakbeat, Rene Lavice, Felix Samuel, DeVice, Bloque, Blean, Interstellar Audio, S.P.Y, ALIBI, flowanastasia, Shogun Audio, Lexed, MAD1AD, Etherwood, UKF, InMost, Fae Vie, Telomic, DuoScience, Rezilient, Dux n Bass, EPITOME, LMX, Kubiks, Pyxis, Alpha Rhythm, Goldfat Records, Hybrid Minds, Lyvia, Melic, DistroKid, Close Inside, Dihanie, Ninkid, Perfect Pitch, Solar Vision, You Love Dance, Sam M, Ridmic, Jolliffe, Sydney Bryce, DrumAndBassArena, Lee Mvtthews, Kate McGill, DIMOD, BazAan, T And Sugah, Amber Jay, Feint, Maduk, Tengu, YosH, Artificial Intelligence, Genetics, Amber Jay, Holy Polly, NMA, Frameshift, Twintone, DNBB Digital, Wardown, Blu Mar Ten Music, Future Shock, Impact Music, Liquefaction, LW Recordings. Tracklist 01. Makoto Ft. Lauren Archer - Invincible [Liquicity Records] 02. Nkz - Bye Bye Darling [Lizplay Records] 03. Nicky Romero x Vikkstar x Alpharock x Oaks - Where Do I Go (Rameses B Extended Remix) [Protocol Recordings] 04. Genemo, YUNA and Saralia - Let Go (Goodbye) [Munix Records] 05. Freaks and Geeks, Flowidus and Gia Santho - Out My Head [Elevate Records] 06. ALSO and Plasmator - Open Your Eyes [Manifest] 07. Andromedik - Air (ft. Lauren L'aimant) [Andromedik] 08. Akos Gyorfy and Kelle - Bastard [Celsius Recordings] 09. Friction - Remember (Circadian Remix) [Elevate Records] 10. Fallen State - What You've Done [Mathematica Records] 11. Kleu - Fading Away (Dub Mix) [LoveThatBass] 12. Receptor and Paperclip - Long Story [Paperfunk Recordings] 13. Voicians - Back In Time [Liquicity Records 14. Receptor - Maybe You Could [Paperfunk Recordings] 15. Gentlemens Club and Lee Mvtthews - Frequency [DnB Allstars] 16. Marble Elephant - Melancholia [Celsius Recordings] 17. Fallen State - Open Mind [Mathematica Records] 18. Monika - Joanna [Spearhead Records] 19. Cyazon and Gracie Van Brunt - My Way Out [Bassrush Records] 20. K2T & DA TU - Unwavering Spirit [Offworld Recordings] 21. Technimatic - Only Dreamers (ft. Zara Kershaw) [Technimatic Music] 22. Keeno - Lights On (Polaris Remix) [Keeno Music] 23. Koven and AEON MODE - Polarised [Monstercat] 24. Modest Intentions and Formulus - Magnetize [Liquicity Records] 25. Park Shadow - Breach [Straight Up Breakbeat] 26. Andromedik - Time [Liquicity Records] 27. Rene Lavice ft. Felix Samuel - Count On You (Extended Mix) [DeVice] 28. Bloque and Blean - The Descent [Interstellar Audio] 29. S.P.Y x ALIBI x flowanastasia - This Is Goodbye [Shogun Audio] 30. Lexed, MAD1AD - It's Not Over [Manifest] 31. Etherwood - Sinking Sand [UKF] 32. Keeno x InMost x Fae Vie - To Feel OK Again (Telomic Remix) [Keeno Music] 33. DuoScience and Rezilient - Tread Lightly [Celsius Recordings] 34. Dux n Bass - Shootingstars [EPITOME] 35. Andromedik - Nothing Like You [Liquicity Records] 36. LMX and Kubiks - See Through [Liquicity Records] 37. Pyxis and Alpha Rhythm - Wanna Say Goodbye [Goldfat Records] 38. Hybrid Minds and Lyvia - Tear Drops [UKF] 39. Melic - Again [DistroKid] 40. Close Inside - Hybrolife [Dihanie] 41. Ninkid, Perfect Pitch and Solar Vision – The Power of Love [You Love Dance] 42. Marble Elephant - Carbon [Celsius Recordings] 43. Sam M - Close To The Edge [Ridmic] 44. Jolliffe and Sydney Bryce - Everything I Know [DrumAndBassArena] 45. Pyxis and Alpha Rhythm - Hummingberg [Goldfat Records] 46. Lee Mvtthews and Kate McGill - Take Me Anywhere [Elevate Records] 47. DIMOD and BazAan - Call Me [Lizplay Records] 48. T and Sugah - Euphoria (ft. Amber Jay) [Liquicity Records] 49. Scatterbrain and HumaNature - Second Thoughts (Subliminal Remix) [Fokuz Recordings] 50. Feint - Divided Sky [Liquicity Records] 51. Maduk - Stay Like This (Telomic Remix) [Liquicity Records] 52. Tengu x Emma Cannon - Coming Back To Me [YosH] 53. Artificial Intelligence and Makoto - Cold Expanse [Liquicity Records] 54. Genetics and Amber Jay - Escape [Ridmic] 55. Holy Polly - Breathe In [NMA] 56. Frameshift and Twintone - For Want Of You [DNBB Digital] 57. Wardown - And They Fell [Blu Mar Ten Music] 58. Future Shock - Alone Again [Impact Music] 59. Liquefaction - Tell Me [LW Recordings] 60. Wardown - No New Messages [Blu Mar Ten Music]

A prince amongst priests. A God amongst men. The darkness is your home, but be careful: what happens when the light is shone on your mortality?Content warnings for this episode include: shadows & the dark // nepotism // corruption // religious overtones // power dynamics // greed // uninvited entry // condescension // violence // premeditated murderGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. The voice of Ashmedai is Cody Heath. The voice of Avaris Kerschel, The Scion of Perdition, is Brennan Lee Mulligan. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

You have to run, you have to. You cannot fight the inevitable. And you have to remember that you can't fight the reality of what's right in front of you. What you see, what you know, and what you want. Content warnings for this episode include: grief // loss // death of a parent // parent-child conflict // gaslighting // being watched, pursed, & chased // burns & wounds // romance // heartbreak // threats of violence & persecution // systemic oppression and corruptionGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

Do you remember when you were made from the mud? How long have you been alone? Did your father want you? And who will save you when the Scion turns his gaze on you?Content warnings for this episode include: grief // loss // death of a parent // parent-child conflict // romance // heartbreak // threats of violence & persecution // systemic oppression and corruptionGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. The voice of Davos Halassian is Christian Carlson. The voice of Avisan Eutoches is Tim Carlson. The voice of Ashmedai is Cody Heath. The voice of Avaris Kerschel, The Scion of Perdition is Brennan Lee Mulligan. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs composed by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

We reflect on the big news of the year and discuss some big stories and releases for each camera brand. Also, today's question is: do you touch the back screen of your mirrorless camera to set focus? New announcement: You can now support us on Patreon! The weekly show will be staying exactly the same, but if you want to contribute to our hosting costs for the podcast, we'd welcome your support. You can check it out here: https://www.patreon.com/cameragearpodcast Want to send us a question or comment, or just learn more about the show? Check out our website at https://cameragearpodcast.com, or email us directly at cameragearpodcast@gmail.com. Some links below to product sites are affiliate links and may result in a commission to the Camera Gear Podcast. Links: Canon Sigma Introduces Lenses for Canon RF Mount Canon R5 II Press Release We covered the Canon R5 II in episode 95 Fuji Fujifilm X100VI Press Release Fujifilm X-M5 Press Release We covered the X100VI in episode 74 We covered the X-M5 in episode 106 Leica Leica Q3 43 Leica D-Lux 8 We covered the Leica Q3 43 in episode 108 We covered the Leica D-Lux 8 in episode 92 Pixii Pixii Max We covered Pixii (although not this camera) in episode 49 Nikon / RED Nikon to Acquire US Cinema Camera Manufacturer RED Nikon Z6III Press Release We covered Nikon buying RED in episode 76 We covered the Nikon Z6III in episode 91 OM System OM-1 Mark II Press Release We covered the OM-1 Mark II in episode 77 Panasonic Panasonic S9 Press Release We covered the Panasonic S9 in episode 88 Pentax / Ricoh Pentax 17 Ricoh GRIII HDF We covered the Pentax 17 in episode 90 We covered the Ricoh GRIII HDF in episode 80 Sony Sony A9 III Press Release Sony A1 II Sony 28-70 f/2 GM We covered the Sony A9 III in episode 60 We covered the Sony A1 Ii in episode 113 We covered the Sony 28-70 f/2 in episode 113 Blackmagic Blackmagic Ursa Cine 12K Blackmagic Pyxis 6K We covered the Ursa Cine 12K and Pyxis in episode 84

Join us for an exclusive interview with the talented voice actress Mary Morgan! Known for her roles in hit series like Fairy Tail and Negima! Magister Negi Magi, Mary shares her journey into voice acting, behind-the-scenes stories, and insights into bringing beloved characters to life. Whether you're a fan of her work or curious about the art of voice acting, this conversation is packed with inspiration and fun. Don't forget to like, comment, and subscribe for more interviews with your favorite voice actors!Want to dive behind the scenes of voice acting? Check out this playlist filled with interviews from top voice actors talking about their experiences in anime, video games, and more: • Voices of the Industry ==============================Connect With Us!==============================TikTok: / movementradio IG: / movementradio3 BlueSky: https://bsky.app/profile/movementradi...Twitter/X: https://x.com/MovementRadio3Facebook: / movementradio2019 Threads: https://www.threads.net/@movementradio3==============================Subscribe & Listen to the Movement Radio Podcast!==============================YouTube: / @movementradio Apple: https://podcasts.apple.com/us/podcast...Spotify: https://open.spotify.com/show/3vfGZJD...

There is comfort in being lost. There is hope in being found. There is fear in being truly seen and known, but it is worth it in the end. Content warnings for this episode include: grief // loss // allusions to pre-meditated murder // parent-child conflict // betrayal // romance // heartbreakGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

Peter Dickstein is a 35-year business leader (Founder, CEO, CFO, and strategy advisor). He is Founder of ShadyPower Technologies, developer of a proprietary, patent-pending IOT technology platform for climate-sustainable, enhanced comfort outdoor work and living. He is Co-Founder of TAPS, a machine-learning consultancy focused on sales lead optimization and churn prevention. He is Chairman (Emeritus) and Co-Founder of Solful (www.solful.com), a California-based branded destination cannabis dispensary company and a guest lecturer at universities including the Haas School of Business at UC Berkeley. He has served in CEO, Chairman, and other C-Suite roles for IOT, SAAS, cleantech, and travel insurance companies. In 1999 Peter founded and served as CEO of eProsper, Inc. (ultimately acquired by Morgan Stanley in 2018 for $900MM) whose patented, SAAS capitalization management system (“CapMx”) became the industry gold standard in the early 2000s and is used today by more than 6,000 venture-funded companies and their corporate law firms. Peter served as CFO for several medical device and technology companies including TruMed Systems, Inc., EndoTex Interventional Systems (acquired by Boston Scientific) and Atrionix (acquired by Johnson & Johnson). He was an EIR at Los Alamos National Laboratory where he identified and helped commercialize technology including Acoustic Cytometry Systems (acquired by Thermo Fisher Scientific) and architected the Los Alamos Venture Acceleration Fund. In the early 90s Peter negotiated a $500MM vendor financing facility for Pyxis Corporation (ultimately acquired by Becton Dickinson for $12BB) with GE Capital that rapidly accelerated Pyxis' market penetration and provided non-dilutive growth capital in lieu of equity. In addition to his general management roles, Peter has initiated, organized, negotiated, and completed numerous equity, debt, and M&A transactions with angel, institutional and strategic investors, and lenders. He has managed functional areas including product development and engineering, sales, service, finance and administration, and external relationships with investors, contract manufacturers, investment bankers, banks, attorneys, and auditors. Peter has served on the boards of Friends of the Urban Forest, the San Francisco Day School, and multiple companies. He is a dual citizen of the United States and Germany. He holds a B.A. from the University of Pennsylvania and a M.B.A. from The Wharton School.

It's time to stop dreaming, because the real world is banging on your door. The City of Glass demands your attention, as you look to find what's lost…Content warnings for this episode include: violence // body horror // police brutality // animal endangerment // death // murder // grief // loss // romance // heartbreak // being chased // ulterior motivesGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. Cartography for this series by Chaim Holtjer of Chaim's Cartography. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

We find Ever on her own journey through the Dreamscape, as she searches for answers about the path she and Rake now walk…Content warnings for this episode include: grief // romance // omission of truth // pain & superficial woundsGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. Cartography for this series by Chaim Holtjer of Chaim's Cartography. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

As Rake fails to dream, something else awaits in the liminal space between sleep and awake…Content warnings for this episode include: Sleep paralysis // Body horror // creature horror & teeth // threats of violence Godkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. Cartography for this series by Chaim Holtjer of Chaim's Cartography. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, promising new TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies. TRANSCRIPT Dr. Ryan Augustin: Hello, I'm Dr. Ryan Augustin, your guest host of the ASCO Daily News Podcast today. I'm a medical oncology fellow at Mayo Clinic in Rochester, Minnesota. Joining me today is Dr. Jason Luke, an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center. I had the privilege of working as a postdoc in Jason's translational bioinformatics lab, where we investigated mechanisms of resistance to immunotherapy in melanoma and other cancers.  Today, we'll be discussing 3 important topics, including neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, the impact and practical considerations for incorporating TIL therapy into melanoma, and the current and future use of CD3 engagers in both uveal and cutaneous melanoma.  You'll find our full disclosures in the transcript of this episode.  Jason, it's great to have this opportunity to speak with you today. Dr. Jason Luke: Absolutely. Thanks, Ryan. It's great to see you. Dr. Ryan Augustin: So, to kick things off, Jason, we, of course, have seen tremendous advances in cancer immunotherapy, not only in metastatic disease but also the perioperative setting. Recent data have shown that the use of neoadjuvant therapy can provide not only critical prognostic information but can also help individualize post-resection treatment strategies and potentially even eliminate adjuvant therapy altogether in patients who achieve a pathologic, complete response. This signifies a conceptual shift in oncology with the goal of curing patients with immunotherapy. In triple-negative breast cancer, the KEYNOTE-522 regimen with pembrolizumab is standard of care. In non-small cell lung cancer, there are now four FDA approved chemo-IO regimens in both the neoadjuvant and perioperative settings. And, of course, in melanoma, starting with SWOG S1801 utilizing pembro mono therapy, and now with combined CTLA-4 PD-1 blockade based on results from the NADINA trial, neoadjuvant IO is the new standard of care in high-risk, resectable melanoma. It's important to highlight this because whereas other tumor types have more mature multidisciplinary care, for example, patients with breast cancer are reviewed by the whole team in every center, and every patient with lung cancer certainly benefits from multidisciplinary care conferences, that's not always the case with melanoma, given the relative frequency of cases compared to other tumor types.  Jason, would you say that we have now moved into an era where the integration of a multidisciplinary team and melanoma needs to be prioritized. And why is it important to have multidisciplinary team coordination from the onset of a patient's diagnosis? Dr. Jason Luke: Well, I think those are great questions, Ryan, and I think they really speak to the movement in our field and the great success that we've had integrating systemic therapy, particularly immunotherapy, into our treatment paradigms. And so, before answering your question directly, I would add even a little bit more color, which is to note that over the last few years, we've additionally seen the development of adjuvant therapy into stages of melanoma that, historically speaking, were considered low-risk, and medical oncologists might not even see the patient. To that, I'm speaking specifically about the stage 2B and 2C approvals for adjuvant anti-PD-1 with pembrolizumab or nivolumab. So this has been an emerging complication.  Classically, patients are diagnosed with melanoma by either their primary care doctor or a dermatologist. Again, classically, the next step was referral to a surgeon who had removed the primary lesion, with discussion around nodal evaluation as well. And that paradigm has really changed now, where I think integration of medical oncology input early on in the evaluation of the appropriate treatment plan for patients with melanoma is quite a pressing issue now, both because we have FDA approvals for therapeutics that can reduce risk of recurrence, and whether or not to pursue those makes a big difference to the patient for discussion early on.  And, moreover, the use of systemic therapies now, prior to surgery, of course, then, of course, requires the involvement of medical oncology. And just for an emphasis point on this, it's classically the case, for good reason, that surgeons complete their surgery and then feel confident to tell the patient, “Well, we got it all, and you're just in really good shape.” And while I understand where that's coming from, that often leaves aside the risk of recurrence. So you can have the most perfect surgery in the world and yet still be at very high risk of recurrence. And so it's commonly the case that we get patients referred to us after surgery who think they're just in totally good shape, quite surprised to find out that, in fact, they might have a 20% to 50% risk of recurrence. And so that's where this multidisciplinary integration for patient management really does make a big difference.  And so I would really emphasize the point you were making before, which is that we need multidisciplinary teams of med onc with derm, with surgery early on, to discuss “What are the treatment plans going to be for patients?” And that's true for neoadjuvant therapy, so, for palpable stage 3, where we might give checkpoint inhibitors or combinations before surgery. But it's true even in any reasonably high-risk melanoma, and I would argue in that state, anything more than stage 1 should be discussed as a group, because that communication strategy with the patient is so important from first principles, so that they have an expectation of what it's going to look like as they are followed out over time. And so we're emphasizing this point because I think it's mostly the case at most hospitals that there isn't a cutaneous oncology disease management meeting, and I think there needs to be.  It's important to point out that usually the surgeons that do this kind of surgery are actually either the GI surgeons who do colon cancer or the breast surgeons. And so, given that melanoma, it's not the most common kind of cancer, it could easily be integrated into the existing disease review groups to review these cases. And I think that's the point we really want to emphasize now. I think we're not going to belabor the data so much, but there are enormous advantages to either perioperative or adjuvant systemic therapy in melanoma. We're talking about risk reduction of more than 50%, 50-75% risk reduction. It's essential that we make sure we optimally offer that to patients. And, of course, patients will choose what they think is best for their care. But we need to message to them in a way that they can understand what the risks and benefits of those treatments are and then are well set up to understand what that treatment might look like and what their expectations would be out over time.  So I think this is a great art of medicine place to start. Instead of belaboring just the details of the trial to say, let's think about how we take care of our patients and how we communicate with them on first principles so that we can make the most out of the treatments that we do have available. Dr. Ryan Augustin: That's great, Jason. Very insightful points. Thank you.  So, shifting gears now, I'd also like to ask you a little bit about TIL therapy in melanoma. So our listeners will be aware that TIL is a promising new approach for treating advanced melanoma and leverages the power of a patient's cytotoxic T cells to attack cancer cells. While we've known about the potential of this therapy for some time, based on pioneering work at the NCI, this therapy is now FDA approved under the brand AMTAGVI (Lifileucel) from Iovance Biotherapeutics, making it the first cellular therapy to be approved for a solid tumor. Now, I know TIL therapy has been administered at your institution, Jason, for several years now, under trial status primarily for uveal melanoma using an in-house processing. But for many cancer centers, the only experience with cellular therapy has come under the domain of malignant hematology with CAR T administration. At our institution, for example, we have only recently started administering TIL therapy for melanoma, which has required a tremendous multidisciplinary effort among outpatient oncology, critical care, and an inpatient hematology service that has expertise in cytokine release syndrome.  Jason, where do you see TIL therapy fitting into the metastatic space? Which patients do you think are truly candidates for this intensive therapy? And what other practical or logistical considerations do you think we should keep in mind moving forward? Dr. Jason Luke: Well, thanks for raising this. I think the approval of lifileucel, which is the scientific name for the TIL product that's on the market now. It really is a shift, a landscape shift in oncology, and we're starting in melanoma again, as seems to be commonly the case in drug development. But it's really important to understand that this is a conceptually different kind of treatment, and therefore, it does require different considerations. Starting first with data and then actualization, maybe secondarily, when we see across the accelerated approval package that led to this being available, we quote patients that the response rate is likely in the range of 30%, maybe slightly lower than that, but a meaningful 25% to 30% response rate, and that most of those patients that do have response, it seems to be quite durable, meaning patients have been followed up to four years, and almost all the responders are still in response. And that's a really powerful thing to be able to tell a patient, particularly if the patient has already proceeded through multiple lines of prior standard therapy. So this is a very, very promising therapy.  Now, it is a complicated therapy as well. And so you highlighted that to do this, you have to have a tumor that's amenable for resection, a multidisciplinary team that has done a surgery to remove the tumor, sent it off to the company. They then need to process the TIL out of the tumor and then build them up into a personalized cell product, bring it back, you have to lympho-deplete the patient, re-introduce this TIL. So this is a process that, in the standard of care setting under best circumstances, takes roughly six weeks. So how to get that done in a timely fashion, I think, is evolving within our paradigms. But I think it is very important for people who practice in settings where this isn't already available to realize that referring patients for this should be a strong consideration. And thinking about how you could build your multidisciplinary team in a way to be able to facilitate this process, I think is going to be important, because this concept of TIL is relevant to other solid tumors as well. It's not approved yet in others, but we kind of assume eventually it probably will be. And so I think, thinking through this, how could it work, how do you refer patients is very important.  Now, coming back to the science, who should we treat with this? Well, of course, it's now an air quotes “standard of care option”, so really it ought to be available to anybody. I will note that currently, the capacity across the country to make these products is not really adequate to treat all the patients that we'd want. But who would we optimally want to treat, of course, would be people who have retained a good performance status after first line therapy, people who have tumors that are easily removable and who have not manifested a really rapid disease progression course, because then, of course, that six-week timeline probably doesn't make sense. The other really interesting data point out of the clinical trials so far is it has looked like the patients who got the least amount of benefit from anti-PD-1 immunotherapy, in other words, who progressed immediately without any kind of sustained response, those patients seem to have the best response to TILs, and that's actually sort of a great biomarker. So, this drug works the best for the population of patients where checkpoint inhibitors were not effective. And so as you think about who those patients might be in your practice, as you're listening, I think prioritizing it for primary progression on anti PD-1, again and giving it ahead thought about how would you get the patient through this process or referred to this process very quickly is really important because that lag time is a problem. Patients who have melanoma tend to progress reasonably quickly, and six weeks can be a long time in melanoma land. So, thinking ahead and building those processes is going to be important moving into the future Dr. Ryan Augustin: Definitely appreciate those practical considerations. Jason, thank you.  Moving on to our final topic, I was hoping to discuss the use of immune cell engagers in melanoma. So, similar to CAR T therapy, bispecific T-cell engagers, or BiTEs, as they're commonly known, are standard of care in refractory myeloma and lymphoma. But these antibodies engaging CD-3 on T cells and a tumor specific antigen on cancer cells are relatively new in the solid tumor space. Tarlatamab, which is a DLL-3 and CD-3 bispecific antibody, was recently approved in refractory small cell lung cancer, and, of course, tebentafusp, an HLA-directed CD-3 T cell engager was approved in uveal melanoma in 2022. Both T and NK cell engaging therapies are now offering hope in cancers where there has historically been little to offer. However, similar to our discussion with TIL therapy, bispecifics can lead to CRS and neurotoxicity, which require considerable logistical support and care coordination.  Jason, I was wondering if you could briefly discuss the current landscape of immune cell engagers in melanoma and how soon we may see these therapies enter the treatment paradigm for cutaneous disease. Dr. Jason Luke: I think it is an exciting, novel treatment strategy that I think we will only see emerge more and more. You alluded to the approval of tebentafusp in uveal melanoma, and those trials were, over the course of a decade, where those of us in solid tumor land learned how to manage cytokine release syndrome or the impact of these C3 bispecifics, in a way that we weren't used to. And what I'll caution people is that CRS, as this term, it sounds very scary because people have heard of patients that, of course, had difficult outcomes and hematological malignancies, but it's a spectrum of side effects. And so, when we think about tebentafusp, which is the approved molecule, really what we see is a lot of rash because GP100, the other tumor antigen target, is in the skin. So, patients get a rash, and then people do get fevers, but it's pretty rare to get more than that. So really what you have to have is the capacity to monitor patients for 12 hours, but it's really not more scary than that. So it really just requires treating a few people to kind of get used to these kinds of symptoms, because they're not the full-on ICU level CRS that we see with, say, CAR T-cells.  But where is the field going? Well, there's a second CD3 bispecific called brenetafusp that targets the molecule PRAME, that's in a phase 3 clinical trial now for frontline cutaneous melanoma. And tebentafusp is also being evaluated in cutaneous melanoma for refractory disease. So, it's very possible that these could be very commonly used for cutaneous melanoma, moving into, say, a two-to-four-year time horizon. And so therefore, getting used to what are these side effects, how do you manage them in an ambulatory practice for solid tumor, etc., is going to be something everyone's going to have to learn how to deal with, but I don't think it should be something that people should be afraid of.  One thing that we've seen with these molecules so far is that their kinetics of treatment effect do look slightly different than what we see with more classic oncology therapies. These drugs have a long-term benefit but doesn't always manifest as disease regression. So, we commonly see patients will have stable disease, meaning their tumor stops growing, but we don't see that it shrank a lot, but that can turn into a very meaningful long-term benefit. So that's something that we're also, as a community, going to have to get used to. It may not be the case we see tumors shrink dramatically upfront, but rather we can actually follow people with good quality- of-life over a longer period of time.  Where is the field going? You mentioned tarlatamab in small cell lung cancer, and I think we're only going to see more of these as appropriate tumor antigens are identified in different tumors. And then the other piece is these CD3 engagers generally rely upon some kind of engagement with a T cell, whether CD3 engagers, and so they can be TCR or T-cell receptor-based therapies, although they can be also SCFV-based. But that then requires new biomarkers, because TCR therapy requires HLA restriction. So, understanding that now we're going to need to profile patients based on their germline in addition to the genomics of the tumor. And those two things are separate. But I would argue at this point, basically everybody with cutaneous melanoma should be being profiled for HLA-A(*)0201, which is the major T-cell receptor HLA haplotype that we would be looking for, because whether or not you can get access immediately to tebentafusp, but therefore clinical trials will become more and more important.  Finally, in that T-cell receptor vein, there are also T cell receptor-transduced T cells, which are also becoming of relevance in the oncology community and people listening will be aware in synovial sarcoma of the first approval for a TCR-transduced T cell with afamitresgene autoleucel. And in melanoma, we similarly have TCR-transduced T cells that are coming forward in clinical trials into phase 3, the IMA203 PRAME-directed molecule particularly. And leveraging our prior conversation about TILs, we're going to have more and more cellular based therapies coming forward, which is going to make it important to understand what are the biomarkers that go with those, what are the side effect profiles of these, and how do you build your practice in a way that you can optimally get your patients access to all of these different treatments, because it will become more logistically complicated, kind of as more of these therapies come online over the next, like we said, two to four years kind of time horizon. So, it's very exciting, but there is more to do, both logistically and scientifically. Dr. Ryan Augustin: That's excellent. Thanks, Jason, and thank you so much for sharing your great insight with us today on the ASCO Daily News Podcast. Dr. Jason Luke: Thanks so much for the opportunity. Dr. Ryan Augustin: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode, and you can follow Dr. Luke on X, formerly known as Twitter, @jasonlukemd. And you can find me, @RyanAugustinMD. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: @ryanaugustinmd Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Ryan Augustin: No relationships to disclose Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Ever and Rake meet at the Lamp. The glint of the blade, the draw of power. Deals struck, bargains made. You're ready, right?Content warnings for this episode include: Threats of violence // anger // concealed identity // knives as weapons // gaslighting // substance useGodkiller: Balance is performed by Em Carlson, Gina Susanna & Jannes Wessels. This season's dramaturge is Tim Carlson. Special thanks to our campaign artist, Mischi, who you can find @Mischiart on twitter! Our main theme for this episode, Light & Dark, was composed by Sean McRoberts. Character and location leitmotifs by Si Rutherford of Sounds of Adventure. Music and effects by Epidemic Sound. Cartography for this series by Chaim Holtjer of Chaim's Cartography. For more stories, come follow us everywhere at @blackwaterdnd, and make sure to check out our Main Campaign on Monday nights at 8pm PST at twitch.tv/blackwaterdnd. To play your own campaign of Godkiller and dive into your own divinity, go support Godkiller by purchasing the ashcan on itch.io today, with the print version published soon by Evil Hat Productions. This show is made possible by our sponsors who graciously support us playing pretend and having feelings about it. We are grateful to be sponsored by Heroforge, who offer fully customizable miniatures made with their online 3D character creator! Head on over and design your own Godkiller, and get them printed in a variety of materials, including colour printing options! With new content added each week, check out www.heroforge.com to start bringing your character to life! This show is also proudly sponsored by Moonbeam, a better and safer way to stream! Dive into Realms for vibrant community hubs where creators keep 100% of what they earn while protected by Pyxis, a revolutionary moderation tool that learns and adapts to your boundaries. So check them out and join Moonbeam today! Finally, we're thankful for our Patrons for joining us on our second journey through the Cradle. You too can come join us on Patreon, where you can check out behind the scenes info, our talkback show Chatwater, as well as exclusive Godkiller bonus content and so much more. Head on over to patreon.com/blackwaterdnd for all the info. See you next time, heretics, and to all the gods out there, be safe!

Episode 239: What hidden insights can customer behavior data analysis reveal about how successful one food delivery app may be over another? Discover how analysis of externally sourced customer behavior data can fuel dramatic improvements in revenue forecasts and strategic decisions. See how competitor data analysis can help identify strengths and weaknesses that are otherwise hidden. In this episode of Customer Confidential, we're joined by Dan McCarthy, director and co-founder of Theta and Associate Professor of Marketing at the University of Maryland's Robert H. Smith School of Business. Dan shares findings from Theta and Bain & Company's jointly published consumer purchase data study, “Customer Lifetime Value across Food Delivery Competitors.” Together, Dan and Rob explore how they used a proprietary database of credit card transaction data from Pyxis to track customer behavior for subscription services over five years. They describe how accounting for corresponding economic factors like seasonality and the Covid-19 pandemic helped improve forecasts of transaction velocity, spending, and retention. Learn which food delivery app had the best customer loyalty, the most customers, and highest per-customer spending. Guest: Dan McCarthy, Director and Co-Founder of Theta, Associate Professor of Marketing at the University of Maryland, College Park Host: Rob Markey, Partner, Bain & Company Give Us Feedback: We'd love to hear from you. Help us enhance your podcast experience by providing feedback here in our listener survey. Want to get in touch? Send a note to host Rob Markey here. Time-Stamped List of Topics Covered: [02:00] Introduction to customer behavior analysis and business forecasting [05:15] How companies can use historical data to predict customer lifetime value [10:00] Insights from customer data and the role of subscription services [15:30] The impact of external factors like economic shifts and market changes on consumer behavior [20:00] How businesses can improve acquisition and retention strategies using data [25:00] Using customer lifetime value to forecast future revenue and business growth Time-Stamped Notable Quotes: [02:45] “The notion of having a consistent data set with multiple companies in it so you can compare … all these different food delivery companies [means] you can explicitly see them and you can see the same consumers buying across them.” [05:37] “It's primarily taking these different vintages of customers—where a vintage is defined by, ‘When did that customer make their very first purchase with your firm?'—and then within that vintage, what we want to explain is what these individual customers are going to do in the future.” [07:42] “[The data] is what allows us to say things like, is this company acquiring customers well? Are they retaining customers well? How frequently are they buying? And how does that compare across different companies?” Additional Resources: Customer Lifetime Value across Food Delivery Competitors Pyxis by Bain & Company

Hello and welcome to The Stress Factor Drum and Bass Podcast episode 315, featuring the highly anticipated return of DJ B-12. This episode presents an extraordinary 100 Track super mix that encapsulates the essence of contemporary drum and bass, showcasing the genre's most exhilarating and cutting edge tracks. Listeners can expect a rich tapestry of sound, characterized by stunning vocals, emotive breakdowns, and a blend of darker, edgier elements that add depth to the mix. The infusion of trancey and electro influences further elevates the listening experience, making this episode a must listen for enthusiasts of high energy music. We invite you to immerse yourself in this remarkable auditory journey and share the excitement with fellow music lovers. This episode includes tunes and remixes from the following artists and labels DC Breaks, Viper Recordings, Metrik, Insomniac Music Group, Houndeye, Delta Heavy, Grafix, Hospital Records, Lexurus, Polygon, Liquicity, ShockOne, Dark Machine Recs, SiLi, Lauren Laimant, Dualistic, Koven, A.M.C, UKF, Aktive, Maduk, Crooked Bangs, Fred V, 1991, Alex Hosking, Chaos, Madface, Dawn Wall, Anni, Bungle, Scientific, Itro, Slippy, Josh Rubin, NCS, Sola, Pyxis, Dirtbox Recordings, Zero T, The North Quarter, Hazey, Ponz, Hiraeth, Prospex, Audio Overload Jungle Records, Fourward, Elevate Record, High Contrast, Highly Contrasting, Seba, Phil Tangent, Secret Operations, Wyld Dogz, Sharlene Hector, Nero, Create Music Group, Andy C, Becky Hill, Polydor Records, Andromedik, Nu-La, Malaky, Galacy Records, DJ Phantasy, Nicky Blackmarket, Lords Of Rave, Sweet Female Attitude, Lords of Moondance, L-Side, NUFORM, Low Steppa, Kelli-Leigh, Shapes, Armada Music, Polaris, Innerground Records, Bastion, Fade Black, Leo Law, Pilot., Skepsis, Brodie, FFRR, Critical Music, Jon Void, Kastuvas, Gas Pedal, Leony, Sigma, Kontor Records, Voicians, Krakota, Lee Mvtthews, Sleepless Music Ltd., Minos, Fokuz Recordings, Drumsound & Bassline Smith, Technique Recordings, Neuron, Celsius Recordings, 3Beat, Sub Focus, Pola & Bryson, EMI, McLean, Camo & Krooked, Asylum Records, Disciples, Delilah, MONSS, Ministry of Sound Recordings, Georgie Riot, Spaven, Riot Record, Hiraeth, Grum, Natalie Shay, Grafix, Anjunabeats, Eviya, Sonny Fodera, blythe, SOLOTOKO, Dogzone Records, Outerbass, Fokuz Recordings, ZeroZero, Riya, Flexout Audio, Virtue, xJAK Audio, Brookes Brothers, Mia Kirkland, The Prototypes, Lowes, Danny Byrd, S.P.Y., CmdCtrl, DnB Allstars, Jazmine Johnson, James Hiraeth, Insanity Records, Iklektix, Beta Recordings, Cauzer, Matrix, Futurebound, Blaine Stranger, Tom Cane, Rex Hooligan, Chrissie Huntley, Camelphat, Sony Music Entertainment UK, Artificial Intelligence, Artino, Flux Pavilion, Matthew Koma, Circus, Oliver Tree, Atlantic Records, Arielle Free, GHSTGHSTGHST, Flava D, Telomic, Dimension, Alison Wonderland, SOLR, GEST, Shogun Audio, Moore Kismet, Rameses B, Monstercat, Rhode, Chicane, Bryan Adams, Monika, Spearhead Records, AR CO, ARTY, Etherwood, Jay Sorrow, Aluna, Picard Brothers, Kaleena Zanders, DRIIA, Mad Decent, SACHI, Kanine, Casablanca Records, Republic Records. Tracklist 01. DC Breaks - Exoplanet [Viper Recordings] 02. Metrik - Immortal [Insomniac Music Group] 03. Houndeye - Falling Awake [Viper Recordings] 04. Delta Heavy - Midnight Forever [Delta Heavy] 05. Grafix - Skyline (ft. Metrik) [Hospital Records] 06. Lexurus and Polygon - Waveline [Liquicity] 07. Polygon - Feel This Good [Liquicity] 08. ShockOne - Follow Me [Dark Machine Recs] 09. SiLi - TRONCE [Liquicity] 10. Delta Heavy - Sanctuary (ft. Lauren Laimant) [Delta Heavy] 11. Dualistic - Cluster Patrol [Liquicity] 12. Koven and A.M.C - Hooked [UKF] 13. Aktive - Loko [UKF] 14. Maduk and Lexurus - Follow My Heart (ft. Crooked Bangs) [UKF] 15. Fred V - Luminous [Hospital Records] 16. 1991 - Jungle (ft. Alex Hosking) [Chaos] 17. Madface - Paralyzed [Viper Recordings] 18. Dawn Wall - Sinner (ft. Anni)[UKF] 19. Bungle - Arise [Scientific] 20. Itro - Promises [Liquicity] 21. Slippy and Josh Rubin - Crash (Extended) [NCS] 22. Sola and Pyxis - Time Lost [Dirtbox Recordings] 23. Zero T - Don't Know [The North Quarter] 24. Hazey and Ponz - Go Under [Liquicity] 25. Hiraeth - Deep Blue [Liquicity] 26. Prospex - Without You [Audio Overload Jungle Records] 27. Fourward - Show Me Love [Elevate Records] 28. High Contrast - Remember Me [Highly Contrasting] 29. Seba - Eztli (Phil Tangent remix) [Secret Operations] 30. Wyld Dogz - Lola's Theme (feat. Sharlene Hector) (Extended Mix) [Dogzone Records] 31. Nero - The Unknown [Create Music Group] 32. Andy C x Becky Hill - Indestructible (Extended Mix) [Polydor Records] 33. Andromedik and Lexurus - Adrenaline (feat. Nu-La) [Liquicity] 34. Malaky and pyxis - Nimbus [Galacy Records] 35. Delta Heavy - No Gravity [Delta Heavy] 36. DJ Phantasy x Nicky Blackmarket x Lords Of Rave - Say Yes (feat. Sweet Female Attitude)[Lords of Moondance] 37. L-Side - Regret [NUFORM] 38. Low Steppa - Runnin' feat. Kelli-Leigh (Shapes Extended Remix) [Armada Music] 39. Polaris - One More Time [Innerground Records] 40. Bastion and Fade Black - Blood and Gold (ft. Leo Law) [Pilot.] 41. Skepsis and Brodie - Double Vision (Extended) [FFRR] 42. Fade Black - Elysium [Critical Music] 43. Jon Void - LFG [Liquicity] 44. Kastuvas - Tell Me Why [Gas Pedal] 45. Leony - Remedy (Sigma Extended Remix) [Kontor Records] 46. Voicians - Lost At Sea [Liquicity Records] 47. Krakota and Lee Mvtthews - Feel Good [Sleepless Music Ltd.] 48. Minos - Mystic Vibez [Fokuz Recordings] 49. 1991 Ft. Mugatu - Cyclone [Chaos] 50. Drumsound and Bassline Smith - One More Time [Technique Recordings] 51. Neuron - Always Together [Celsius Recordings] 52. Sigma - That Feeling [3Beat] 53. Sub Focus and Pola and Bryson - Waiting VIP (ft. Kelli Leigh) [EMI] 54. McLean - Finally In Love (Camo and Krooked Remix) [Asylum Records] 55. Lexurus - Take Me Away [Liquicity] 56. Disciples x Delilah - If I Stay (MONSS Remix) [Ministry of Sound Recordings] 57. Georgie Riot and Spaven - Out Of My Mind [Riot Records] 58. Hiraeth - Origins (SiLi Remix) [Liquicity] 59. Grum ft. Natalie Shay - Don't Look Down (Grafix Remix) [Anjunabeats] 60. Lexurus and Itro - Letting Go (feat. Eviya) [Liquicity] 61. Sonny Fodera - Mind Still (feat. blythe) (1991 Remix) [SOLOTOKO] 62. Wyld Dogz - Spaceman [Dogzone Records] 63. Outerbass - Radical [Fokuz Recordings] 64. ZeroZero and Riya - Thinking Over It [Flexout Audio] 65. Virtue - Second Guessing [xJAK Audio] 66. Brookes Brothers, Mia Kirkland - Enemies [UKF] 67. The Prototypes - Reason (feat. Lowes) (Danny Byrd Extended Remix) [The Prototypes] 68. Danny Byrd, S.P.Y. and Cmd Ctrl - Pink Champagne [DnB Allstars] 69. Delta Heavy - Chasing Gold (ft. Jazmine Johnson) [Delta Heavy] 70. James Hiraeth - Chasing Highs (Slow Motion) (Extended) [Insanity Records] 71. Iklektix - How I Like It [Beta Recordings] 72. Fade Black - Condemned (Cauzer Remix) [Critical Music] 73. Matrix and Futurebound and Blaine Stranger - New Energy (ft. Tom Cane) [Viper Recordings] 74. Rex Hooligan - Save Me (feat. Chrissie Huntley) [Liquicity] 75. Camelphat - Easier ft. LOWES (Sub Focus Remix) [Sony Music Entertainment UK] 76. Voicians - Keep Me Under [Liquicity] 77. Artificial Intelligence - Even Though [Liquicity] 78. Neuron - No More [Celsius Recordings] 79. Artino - What I Want [Liquicity] 80. Flux Pavilion x Matthew Koma - Emotional (James Hiraeth Remix) [Circus] 81. Outer Bass - Stardrop [Fokuz Recordings] 82. Oliver Tree - Miss You (Georgie Riot Remix) [Atlantic Records] 83. Arielle Free and GHSTGHSTGHST - Blow My Mind (Flava D Extended Remix) [Armada Music] 84. Voicians and Telomic - Eternalize [Liquicity] 85. Dimension and Alison Wonderland - Satellite [Dimension] 86. Neuron - Searching [Celsius Recordings] 87. Fade Black - Far Gone [Critical Music] 88. SOLR - Your Love [Celsius Recordings] 89. Delta Heavy - High On You [Delta Heavy] 90. GEST - Brutalis [Shogun Audio] 91. Moore Kismet - Overthinking Out Loud [UKF] 92. Rameses B - Children [Monstercat] 93. Voicians and Rhode - Never Go Back [Liquicity] 94. Fade Black - Sane feat. Leo Law [Critical Music] 95. Chicane - Don't Give Up feat. Bryan Adams (Grafix Extended Remix) [Armada Music] 96. Monika - Death Blinding [Spearhead Records] 97. Sub Focus - Vibration (One More Time) (Visualiser) ft. AR/CO [EMI] 98. ARTY and Etherwood - In My Head feat. Jay Sorrow (Extended Mix) [Armada Music] 99. Aluna, Picard Brothers and Kaleena Zanders - Supernova (DRIIA Remix) [Mad Decent] 100.SACHI - Take Me Back (Kanine Remix) [Casablanca Records (Republic Records)]

Discover Breakthroughs in Sunflower Oil Wastewater Treatment: A Special Re-Air of Our Most Popular Episode from 2023 When it comes to oil wastewater treatment, the challenges can feel overwhelming. But what if there was a way to tackle these obstacles with cutting-edge solutions? In this special re-airing of our most popular episode from 2023, Swati Sharma, Ph.D. an expert at Water Engineering Inc. (WEI), walks us through her innovative research that's helping water treaters around the world. Her expertise is backed by groundbreaking research, including her thesis titled "How to Estimate the Best Treatment Conditions for Sunflower Oil Wastewater Using Advanced Electrooxidation Process", which she graciously shares with our global audience. Gain insights into electrooxidation processes and valuable advice for aspiring water treatment researchers. Even if you've heard this episode before, we promise you'll learn something new this time around. Dr. Sharma's expertise in electrooxidation processes and her passion for solving complex wastewater problems is sure to inspire and equip you to approach your next challenge with confidence. What makes treating sunflower oil wastewater so difficult? Sunflower oil wastewater is particularly challenging because it contains high levels of organic pollutants. Traditional methods often fall short, leaving treaters frustrated and looking for better solutions. But as Dr. Sharma shares, every wastewater is different, and each treatment process behaves uniquely depending on the specific characteristics. “I found that each wastewater was so different in its characteristics, that each of these treatments behaved completely differently. Electrocoagulation (EC) was really good with the canola oil, whereas I found that Electrooxidation (EO) was a better process for sugar beets, which are really high in organic loading.” – Dr. Swati Sharma How does electrooxidation make a difference? Dr. Sharma explains that advanced processes like electrooxidation and electrocoagulation offer more precise control over treating specific types of wastewaters. Electrooxidation, for instance, can target and break down organic pollutants more effectively than conventional methods, making it a game-changer for sunflower oil wastewater. “Wastewater is like math, it's like a game. You have to understand it and enjoy doing it. It's a puzzle, you need to connect the dots to make a beautiful picture.” – Dr. Swati Sharma What advice does Dr. Sharma have for aspiring researchers? Dr. Sharma's path to success wasn't without challenges. In the episode, she offers valuable insights into the importance of persistence and curiosity. Whether you're a seasoned professional or just starting out, her advice applies across the board. “Sometimes your hypothesis doesn't match your findings and it's hard. You dedicate so many hours of your life to your study and you are so passionate about this, and it's demotivating at times. But you have to learn what has failed and why it has failed. Find the reason behind your failure and it will lead to your success. That's what I believe in.” – Dr. Swati Sharma What's the key to successful wastewater treatment? Understanding the specific characteristics of the wastewater you're dealing with is essential to finding the right solution. Dr. Sharma emphasizes that it's not just about adding chemicals but truly understanding the problem. “It's not about the addition of chemicals, it's about understanding the characteristics of your wastewater. pH, temperature, composition, where is it coming from and where is it going—all of these matters matter. Understanding how this work is important.” – Dr. Swati Sharma Whether you're hearing this episode for the first time or revisiting it, Dr. Sharma's research will leave you better equipped to tackle your next wastewater challenge with new insights and practical takeaways. Timestamps 01:00 - Trace Blackmore reminds you that next week there will be a new episode heard every day as we celebrate all 5 days of Industrial Water Week 06:00 - Introducing our top five episodes since Industrial Water Week 2023 08:03 - Interview with Doctor Swati Sharma of Water Engineering Incorporated, about 43:30 - Drop by Drop with James McDonald Connect with Swati Sharma, Ph.D. Phone: 402.521.4161 Email: ssharma@h2oeng.com Website:  www.h2oeng.com LinkedIn: in/swati-sharma-ph-d-91449518 company/water-engineering-inc Read the Press Release HERE Links Mentioned “How to Estimate the Best Treatment Conditions for Sunflower Oil Wastewater Using Advanced Electrooxidation Process” - Thesis by Dr. Swati Sharma Follow Dr. Swati Sharma on Google Scholar and be updated on her publications The Rising Tide Mastermind Top 5 Episodes since 2023's Industrial Water Week 341 Guarding Against Legionella: The Hidden Dangers of Dead Legs in Water Systems with lab partner Richard Philip Beckett 348 Credentials and Codes: Plumbing Strategies Against Legionella with Christoph Lohr 328 Industrial Water Week 2023: Pretreatment Monday with Wes Bryne 324 Endless Career Possibilities in Industrial Water Treatment with Chelsea Farmer Books Mentioned Wastewater Engineering: Treatment and Resource Recovery by Inc. Metcalf & Eddy Drop By Drop with James  In today's episode, we're thinking about annual reviews. Yes, annual reviews. They come due before you know it each year. Do you do annual reviews for your customers? If your answer is no, why not? I've always found annual reviews to be a great time to remind your customer of the value you bring to their operation. Industrial water treatment is important! Without it, it would cost more for them to operate. In many instances, their operations could be shut down. Plus, there are many safety aspects that good industrial water treatment brings to the table from helping keep boilers from exploding to helping minimize Legionnaires Disease. It's also a good time to get everyone on the same page to both maintain and improve the water treatment operations. Sure, it could be an opportunity for the end user to complain, but that's good! Would you rather they have an opportunity to tell you their issues face to face or in an email informing you they're changing industrial water treatment vendors? Be sure to document the annual review with a prepared document or presentation. Also be sure to follow up on any issues they have and commitments you have made.  Events for Water Professionals Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE. 

How Veolia Prioritizes Health and Safety Worldwide? At Veolia, safety isn't just a requirement—it's embedded in the company's core values. Leading the charge is Arnaud Valleteau de Moulliac, Chief Executive Officer of Veolia Water Technologies. In this week's episode, Arnaud speaks with Scaling UP! H2O host Trace Blackmore about how safety initiatives are reshaping Veolia's culture around the world. Arnaud emphasizes that health and safety are non-negotiable: "It's a 24/7 commitment." This episode takes you inside Veolia's global approach, showing how the company's 8,000+ employees have integrated safety into their daily routines. What Drives Veolia's Health and Safety Initiatives? For Arnaud, safety comes from a personal place: “As a father of four, ensuring everyone gets home safely is paramount.” This family-first approach reflects Veolia's deep commitment to safety, which has been an ongoing focus for over a decade. “Ten years ago, we launched International Health and Safety Week, where every subsidiary worldwide participates in focused discussions and actions on safety.” This annual event creates a space for employees to assess their work environments, recognize potential risks, and form long-lasting safety habits. But at Veolia, safety isn't just about one week—it's about creating a culture that endures year-round. Fostering a Culture of Safety Every Day While International Health and Safety Week serves as a focal point, Veolia's goal is to make safety a daily priority. “We need to ensure that health and safety are part of our everyday routines, not just something we think about once a year,” Arnaud notes. To keep safety top of mind, managers at Veolia conduct at least six field visits each year, evaluating safety practices and identifying areas for improvement. Employees are encouraged to report near-misses and incidents, creating a culture were speaking up about safety is valued. “It's about creating an environment where people feel safe to voice concerns without fear of judgment,” Arnaud says. “Building trust is essential.” A Cultural Shift: Breaking Old Safety Norms One of Veolia's biggest achievements over the last decade has been a shift in how employees view safety. Arnaud recalls a time when raising safety concerns was often seen as a sign of weakness. Today, those conversations are welcomed and encouraged. “There used to be this mentality of being a 'superman'—toughing it out in unsafe conditions. That's behind us now, but we always stay cautious. The human element means we can never stop paying attention to safety,” Arnaud warns. This shift has been a significant victory for Veolia, but the work isn't finished. The company remains vigilant, continually adapting its safety approach to address both evolving risks and human factors. Celebrating 10 Years of Health and Safety Transformation As Veolia marks the 10th anniversary of International Health and Safety Week, Arnaud reflects on the company's progress. One key success has been the reduction in workplace accidents and the increasing willingness of employees to report safety risks. “Ten years ago, speaking up about safety could be seen as a weakness,” Arnaud explains. “Today, it's a sign of strength and responsibility.” This cultural change has transformed how employees view safety—not as a policy, but as a core value that protects their colleagues and ensures everyone returns home safely. Starting a Safety Culture: Insights for Small Teams For small businesses, building a safety culture might seem overwhelming. However, as Arnaud explains, it's not about financial investment—it's about leadership and intention. “Safety starts at the top. Being an exemplary leader doesn't cost anything. It's about creating policies and following through. Take time to sit with your team and ask, ‘What are the risks?' It's an investment in people, not just resources. Any company, no matter its size, can do this,” Arnaud emphasizes. Manager Visits: Fresh Eyes on the Ground As part of Veolia's commitment to safety, manager site visits provide an opportunity for leadership to spot issues that might have become invisible to regular operators. These visits aren't just procedural—they're a chance to bring fresh perspectives into the conversation. “Even non-operational colleagues—those from HR or finance—ask valuable questions during these visits. Their common sense often uncovers risks that might otherwise go unnoticed. Safety is about asking the right questions, not about being an expert,” Arnaud explains. One Key Takeaway: Lead by Example If there's one message Arnaud wants listeners to take away, it's this: “Be exemplary. It starts with you.” Veolia's success in transforming its safety culture is a powerful reminder that leadership and continuous vigilance are the best tools for creating a safe working environment, no matter the size of the operation. Stay Informed and Stay Safe! As Veolia's journey shows, building a culture of health and safety requires effort, commitment, and teamwork. Whether you are part of a large organization or a small team, Arnaud Valleteau de Moulliac's insights offer valuable lessons for promoting safety in any workplace. Timestamps 01:46 - Trace Blackmore thanks you for connecting at AWT last week and thanks you for the Innovation Award 07:54 - Upcoming Events for Water Treatment Professionals 11:13 - Interview with Arnaud Valeteau de Moulliac about his commitment to safety 40:05 - Drop by Drop with James McDonald  Connect with Arnaud Valleteau de Moulliac Email: arnaud.valleteau@veolia.com Website: www.veoliawatertechnologies.com LinkedIn: linkedin.com/in/arnaud-valleteau-de-moulliac-9b85353a/ www.linkedin.com/company/veolia-water-technologies/ Twitter: https://twitter.com/VeoliaWaterTech Read or Download Arnaud Valleteau de Moulliac's Press Release HERE Links Mentioned Ep 358 Safety First: Practical Tips, Big Results in Water Treatment Walk me through this “Safety Third” thing – Mike Rowe The Rising Tide Mastermind Scaling UP! H2O Academy video courses AWT (Association of Water Technologies) Drop By Drop with James  In today's episode, I have a “what if” for you. What if the temperature of the softener regeneration water drops in the wintertime? Now, if you're in an area with a warmer climate year-round, you may not have to worry about this, but for those who live in colder climates, it is something to consider. How could colder water temperatures cause an issue with softener regeneration? Have you ever considered this before? The answer is that water is denser at cooler temperatures. This could be especially important during the backwash step of the softener regeneration. A proper backwash is necessary to ensure efficient softener operation. It loosens the bed, minimizes pressure drop, cleans and classifies the resin, and maintains an even water flow across the cross-sectional area of the resin bed. Backwash flow rates must be high enough to expand the bed by 50% and typically last around 10 minutes or more. If the water is denser because it is colder, the same flow rate used in the warmer months can result in expanding the resin bed even MORE, which could ultimately lead to washing good resin down the drain. Resin manufacturers often have tables that show the required flow rate based upon water temperature. A big picture look at these tables roughly shows that, in Fahrenheit, when the temperature drops to half what it was in the summer months, the required flow rate could drop to half as well. Be sure to always refer to the resin manufacturer's specifications for actual design numbers, though.  2024 Events for Water Professionals Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.   

In today's episode I cover the latest stories from PetaPixel worth talking about this week. You can find the show notes here. https://liamphotographypodcast.com/episodes/episode-418-outdoor-line-pyxis-6k-luminar-neo-more